https://crcwarriors.org/ 2026-06-23 daily 1.0 https://crcwarriors.org/ensayos-clinicos 2026-06-23 daily 0.9 https://crcwarriors.org/medicamentos 2026-06-23 weekly 0.9 https://crcwarriors.org/noticias-cientificas 2026-06-23 daily 0.8 https://crcwarriors.org/noticias 2026-06-23 daily 0.8 https://crcwarriors.org/combinaciones 2026-06-01 weekly 0.8 https://crcwarriors.org/eficacia 2026-06-01 weekly 0.8 https://crcwarriors.org/eficacia/kras 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/braf 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/msi 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/biomarker-unselected 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/her2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/mmr 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/mss 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ras 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3ca 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/nras 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/tp53 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/all 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/apc 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/met 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ddr 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/tmb 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/alk 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/atm 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/smad4 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pten 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ret 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/vegf 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1a 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/mlh1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pd-l1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ccne1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/fbxw7 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ros1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/tie2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/blm 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ccnd1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pole 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb3 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/prex2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/rb1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/brca1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/cdh17 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/mutyh 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pms2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/brca2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr+pathway 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk3 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ctnnb1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/msh2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h%2Fdmmr 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/nf1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/palb2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/actl6b 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/cdkn2a 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/idh1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/keap1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/msh6 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/notch1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pathogenic+variants 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3r1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51d 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/tcf7l2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/wild-type 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/bcl2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/chek2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb4 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr3 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/idh2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/smarca4 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/tgfbr2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1b 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk4 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/cna 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/igf1r 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/line-1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/myc 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/nthl1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pi3k+pathway 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pold1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/sox9 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfa 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/arid2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk6 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/hpv 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/jag1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/map2k1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51c 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf%2Fegfr%2Fpik3ca%2Fmap2k1%2Fmet%2Fret%2Falk%2Fros1%2Fntrk%2F 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/smad2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/stk11 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfr 2026-06-01 monthly 0.7 https://crcwarriors.org/nuestra-historia 2026-06-01 monthly 0.7 https://crcwarriors.org/contacto 2026-06-01 monthly 0.6 https://crcwarriors.org/ayuda 2026-06-01 monthly 0.6 https://crcwarriors.org/colabora 2026-06-01 monthly 0.6 https://crcwarriors.org/ensayo/NCT07659795/un-estudio-de-fase-ii-de-vs-7375-en-pacientes-con-cancer-colorrectal-con-mutacion-kras-g12d 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07659795/a-phase-2-study-of-vs-7375-in-patients-with-kras-g12d-mutated-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07650409/una-intervencion-dietetica-palitos-de-pretzel-de-soja-para-reducir-la-inflamacion-cronica-en-individuos-obesos 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07650409/a-dietary-intervention-soy-soft-pretzels-for-reducing-chronic-inflammation-in-obese-individuals 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07661641/un-estudio-de-177lu-lu-a9-0631-y-225ac-ac-a9-0642-con-68ga-ga-a9-6217-o-imagen-con-177lu-lu-a9-0631-en-tumores-solidos-grpr 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07661641/a-study-of-177lu-lu-a9-0631-and-225ac-ac-a9-0642-with-68ga-ga-a9-6217-or-177lu-lu-a9-0631-imaging-in-grpr-solid-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07656740/manejo-no-quirurgico-y-seguimiento-tras-la-inmunoterapia-en-el-cancer-colorrectal-y-otros-canceres-del-tracto-gastrointestinal 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07656740/non-operative-management-and-following-immunotherapy-for-colorectal-cancer-and-other-gi-cancers 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05378919/terapia-neoadyuvante-frente-a-terapia-estandar-en-el-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05378919/neoadjuvant-therapy-vs-standard-therapy-in-locally-advanced-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06335420/propiedades-profilacticas-del-zumo-de-zanahoria-en-pacientes-con-polipos-colorrectales-de-alto-riesgo 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06335420/prophylactic-properties-of-carrot-juice-in-patients-with-high-risk-colorectal-polyps 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05107674/un-estudio-de-nx-1607-en-adultos-con-tumores-malignos-avanzados 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05107674/a-study-of-nx-1607-in-adults-with-advanced-malignancies 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07406594/cambios-en-el-microbioma-intestinal-durante-la-terapia-con-abemaciclib-en-el-cancer-de-mama 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07406594/gut-microbiome-changes-during-abemaciclib-therapy-in-breast-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06435689/estudio-y-modulacion-de-las-respuestas-inmunitarias-en-los-canceres-colorrectales-primarios-y-metastasicos 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06435689/study-and-modulation-of-immune-responses-in-primary-and-metastatic-colon-cancers 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06124378/tislelizumab-neoadyuvante-en-combinacion-con-quimioterapia-para-el-tratamiento-del-cancer-colorrectal-mss 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06124378/neoadjuvant-tislelizumab-with-chemotherapy-for-the-treatment-of-mss-colon-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06583564/el-efecto-pronostico-de-la-cirugia-guiada-por-fluorescencia-con-verde-de-indocianina-icg-en-la-supervivencia-libre-de-enfermedad-dfs-del-cancer-colorrectal-en-estadio-iii 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06583564/the-prognosis-effect-of-indocyanine-green-icg-fluorescence-guided-surgery-on-disease-free-survival-dfs-of-stage-iii-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06578559/estudio-de-fase-ii-de-encorafenib-mas-cetuximab-con-retratamiento-guiado-por-ctdna-en-pacientes-con-mcrc-con-mutacion-braf-v600e 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06578559/phase-ii-study-of-ctdna-guided-encorafenib-plus-cetuximab-retreatment-in-patients-braf-v600e-mutated-mcrc 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06731998/control-optimo-del-dolor-perioperatorio-en-la-cirugia-abdominal-minimamente-invasiva-para-el-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06731998/optimal-perioperative-pain-control-in-minimally-invasive-abdominal-cancer-surgery 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503639/ensayo-clinico-umbrella-de-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503639/umbrella-trial-of-neoadjuvant-therapy-for-locally-advanced-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04678648/un-ensayo-clinico-de-rsc-1255-para-el-tratamiento-de-pacientes-con-tumores-malignos-avanzados 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04678648/a-trial-of-rsc-1255-for-treatment-of-patients-with-advanced-malignancies 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06301386/everolimus-en-combinacion-con-un-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06301386/everolimus-combined-with-pd-1-in-advanced-colorectal-cancer-patients 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509424/radioterapia-neoadyuvante-de-corta-duracion-seguida-de-una-combinacion-de-disitamab-vedotina-sintilimab-y-capecitabina-en-el-cancer-colorrectal-localmente-avanzado-con-expresion-de-her2 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509424/neoadjuvant-short-course-radiotherapy-followed-by-a-combination-of-disitamab-vedotin-sintilimab-and-capecitabine-in-locally-advanced-her2-expressing-rectal-cance 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07314294/estudio-de-fase-ii-de-emb-01-en-pacientes-con-cancer-colorrectal-recurrente-o-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07314294/phase-ii-study-of-emb-01-in-recurrent-metastatic-colorectal-cancer-patients 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07622017/kortuc-krc-01-mas-radioterapia-para-la-preservacion-de-organos-en-el-cancer-de-recto 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622017/kortuc-krc-01-plus-radiotherapy-for-organ-preservation-in-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06204094/radioterapia-que-preserva-los-ganglios-linfaticos-combinada-con-quimioterapia-neoadyuvante-total-con-capox-y-sintilimab-para-el-cancer-colorrectal-medio-y-bajo-con-mss 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06204094/node-sparing-radiotherapy-combined-with-total-neoadjuvant-capox-and-sintilimab-for-mss-middle-and-low-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06055439/un-estudio-de-fase-1-2-para-evaluar-chm-2101-una-terapia-celular-t-con-receptor-quimerico-de-antigeno-17-car-autologa 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06055439/a-phase-1-2-study-to-evaluate-chm-2101-an-autologous-cadherin-17-chimeric-antigen-receptor-car-t-cell-therapy 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04034173/tratamiento-optimo-con-anti-egfr-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-mutacion-ras-de-baja-frecuencia 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04034173/optimal-anti-egfr-treatment-of-mcrc-patients-with-low-frequency-ras-mutation 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02008656/ensayo-que-evalua-la-supervivencia-libre-de-enfermedad-a-3-anos-en-pacientes-con-cancer-colorrectal-localmente-avanzado-tratados-con-quimiorradiacion-mas-quimioterapia-de-induccion-o-consolidacion-y 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02008656/trial-evaluating-3-year-disease-free-survival-in-patients-with-locally-advanced-rectal-cancer-treated-with-chemoradiation-plus-induction-or-consolidation-chemotherapy-and-total-mesorectal-excision-or 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-mas-radioterapia-y-quimioterapia-para-el-tratamiento-neoadyuvante-del-cancer-de-recto-localmente-avanzado-pucrt 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-plus-radiotherapy-and-chemotherapy-for-neoadjuvant-treatment-of-locally-advanced-rectal-cance-pucrt 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06923345/radioterapia-de-larga-duracion-modificada-seguida-de-quimioterapia-e-inhibidor-de-pd-1-para-pacientes-con-cancer-colorrectal-localmente-avanzado-de-riesgo-alto-y-con-msi-pmmr-estudio-modifi-rc-i 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06923345/modified-long-course-radiotherapy-followed-by-chemotherapy-and-pd-1-inhibitor-for-mss-pmmr-high-risk-mid-low-larc-modifi-rc-i 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06337760/jovenes-adultos-con-canceres-gastrointestinales-y-neuroendocrinos 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06337760/young-adults-with-gastro-intestinal-gi-and-neuroendocrine-cancers 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03179540/manejo-no-quirurgico-del-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03179540/non-operative-management-for-locally-advanced-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06176885/eficacia-y-seguridad-de-la-combinacion-con-inmunoterapia-tras-la-terapia-de-induccion-con-quimioterapia-y-terapia-dirigida-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06176885/efficacy-and-safety-of-combined-with-immunotherapy-after-induction-therapy-with-chemotherapy-and-targeted-therapy-in-the-first-line-treatment-of-microsatellite-stable-mss-initially-unresectable 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07636382/ablacion-del-plexo-celiaco-para-el-dolor-mediante-radioterapia-estereotactica-sin-necesidad-de-simulacion-en-pacientes-con-dolor-celiaco-relacionado-con-el-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07636382/simulation-free-celiac-plexus-pain-ablation-using-stereotactic-body-radiotherapy-in-patients-with-cancer-related-celiac-pain 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07528209/quimioterapia-neoadyuvante-con-capox-con-o-sin-pucotenlimab-mas-radioterapia-selectiva-para-el-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07528209/neoadjuvant-capox-with-or-without-pucotenlimab-plus-selective-radiotherapy-for-locally-advanced-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07200141/aumento-simultaneo-de-la-dosis-en-la-radioterapia-neoadyuvante-para-el-cancer-de-recto 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07200141/simultaneous-boost-in-neoadjuvant-radiotherapy-for-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07116577/radioterapia-combinada-con-ql1706-tas-102-y-bevacizumab-en-mcrc 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07116577/radiotherapy-combined-ql1706-tas-102-and-bevacizumab-in-mcrc 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07645118/braquiterapia-seguida-de-nivolumab-antes-de-la-cirugia-en-el-cancer-de-recto 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07645118/brachytherapy-followed-by-nivolumab-prior-to-surgery-in-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04854213/prelude-1-evaluacion-prospectiva-de-los-efectos-biologicos-inducidos-por-la-radioterapia-en-pacientes-con-enfermedad-oligo-metastasica-de-cancer-colorrectal-y-enfermedad-limitada-a-los-pulmones 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04854213/prelude-1-prospective-evaluation-of-radiotherapy-induced-biologic-effects-in-colorectal-cancer-oligometastatic-patients-with-lung-limited-disease-evolution-of-cancer-genetics-and-regulatory-immune 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07646639/diferentes-dosis-de-radioterapia-estereotactica-scrt-mas-capox-bloqueo-de-pd-1-e-il-2-en-el-cancer-colorrectal-localmente-avanzado-larc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07646639/different-dose-scrt-plus-capox-pd-1-blockade-and-il-2-in-larc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05007132/trifluridina-tipiracil-mas-panitumumab-frente-a-trifluridina-tipiracil-mas-bevacizumab-como-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05007132/trifluridine-tipiracil-plus-panitumumab-versus-trifluridine-tipiracil-plus-bevacizumab-as-first-line-treatment-of-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05523245/prediccion-de-la-eficacia-de-la-terapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-mediante-una-plataforma-de-inteligencia-artificial-basada-en-la-resonancia-magnetica 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05523245/predicting-the-efficacy-of-neoadjuvant-therapy-in-patients-with-locally-advanced-rectal-cancer-using-an-ai-platform-based-on-multi-parametric-mri 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06549907/un-estudio-exploratorio-de-biomarcadores-sobre-el-bloqueo-dual-de-pd1-pdl1-y-ctla4-y-la-terapia-antiangiogenica 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06549907/a-biomarker-exploratory-study-of-dual-blockade-of-pd1-pdl1-and-ctla4-and-anti-angiogenic-therapy 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05219734/el-ensayo-de-enfermedad-residual-minima-erm-evalua-la-recurrencia-y-la-respuesta-mediante-una-evaluacion-basada-en-el-tumor 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05219734/mrd-assay-evaluates-recurrence-and-response-via-a-tumor-informed-assessment 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07038122/reduccion-del-margen-de-reseccion-tras-la-terapia-neoadyuvante-en-canceres-localmente-avanzados-de-la-union-rectosigmoidea-y-del-recto-superior 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07038122/reducing-the-resection-range-after-neoadjuvant-therapy-for-locally-advanced-upper-rectal-and-rectosigmoid-junction-cancers 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03657641/regorafenib-y-pembrolizumab-en-el-tratamiento-de-participantes-con-cancer-colorrectal-avanzado-o-metastasico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03657641/regorafenib-and-pembrolizumab-in-treating-participants-with-advanced-or-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06252142/estudio-que-evalua-si-la-estrategia-de-esperar-y-observar-es-adecuada-en-el-cancer-de-recto 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252142/study-for-wait-and-watch-suitable-in-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07523763/inmunoterapia-neoadyuvante-a-dosis-bajas-en-el-cancer-colorrectal-localmente-avanzado-con-deficiencia-de-mmr 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07523763/neoadjuvant-low-dose-immunotherapy-in-locally-advanced-mmr-deficient-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04928807/radioterapia-de-corta-duracion-seguida-de-quimioterapia-neoadyuvante-y-camrelizumab-en-el-cancer-colorrectal-localmente-avanzado-union 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04928807/short-course-radiotherapy-followed-by-neoadjuvant-chemotherapy-and-camrelizumab-in-locally-advanced-rectal-cancer-union 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07104877/un-estudio-de-sys6010-en-combinacion-con-syh2051-en-pacientes-con-cancer-colorrectal-avanzado-y-otros-tumores-gastrointestinales 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07104877/a-study-of-sys6010-in-combination-with-syh2051-in-patients-with-advanced-colorectal-cancer-and-other-gastrointestinal-tumors 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03426904/quimioterapia-neoadyuvante-con-folfox-para-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03426904/neoadjuvant-folfox-chemotherapy-for-patients-with-locally-advanced-colon-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05507112/time-en-inmunoterapia-combinada-con-quimiorradioterapia-neoadyuvante-en-el-cancer-de-recto 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05507112/time-in-immunotherapy-combined-with-ncrt-for-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03981497/ablacion-por-microondas-para-el-tratamiento-de-tumores-renales-pequenos-y-neoplasias-hepaticas-primarias-y-secundarias 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03981497/microwave-ablation-for-treatment-of-small-renal-tumors-and-primary-and-secondary-liver-neoplasms 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07347951/un-estudio-de-fase-ii-realizado-en-un-unico-centro-sobre-la-eficacia-y-la-seguridad-de-la-combinacion-de-radioterapia-estereotactica-scrt-con-quimioterapia-capox-serplulimab-y-bevacizumab-en 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07347951/a-single-center-phase-ii-study-on-efficacy-safety-of-scrt-capox-serplulimab-bevacizumab-for-mss-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07542262/estudio-clinico-de-fase-ii-abierto-de-un-unico-centro-para-evaluar-la-eficacia-y-la-seguridad-de-la-inmunoterapia-a-dosis-bajas-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-y-cancer-gastrico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07542262/low-dose-immunotherapy-in-metastatic-and-locally-advanced-colorectal-and-gastric-msi-dmmr-cancers 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-en-el-tratamiento-de-pacientes-jovenes-con-gliomas-de-alto-grado-recurrentes-progresivos-o-refractarios-gliomas-intrinsecos-del-tronco-encefalico-difusos-tumores-cerebrales-hipermutados 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-in-treating-younger-patients-with-recurrent-progressive-or-refractory-high-grade-gliomas-diffuse-intrinsic-pontine-gliomas-hypermutated-brain-tumors-ependymoma-or-medulloblastoma 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07355764/ma-crc-ii-016-shr-1811 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06695845/un-estudio-de-fase-2-de-zanidatamab-en-pacientes-con-tumores-que-expresan-her2 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06695845/a-phase-2-study-of-zanidatamab-in-patients-with-her2-expressing-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07154316/ensayo-clinico-fase-ii-aleatorizado-y-controlado-que-compara-la-quimiorradioterapia-neoadyuvante-lcrt-frente-a-la-radioterapia-neoadyuvante-de-corta-duracion-scrt-combinada-con-capox-un-inhibidor-de 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07154316/phase-ii-rct-of-lcrt-vs-scrt-capox-pd-1i-cox-2i-in-mss-locally-advanced-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831669/metabolomica-para-predecir-la-respuesta-al-tratamiento-y-las-toxicidades-en-el-cancer-de-recto 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831669/metabolomics-to-predict-treatment-response-and-toxicities-in-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06052332/eficacia-y-seguridad-de-la-terapia-neoadyuvante-convencional-frente-a-la-terapia-neoadyuvante-total-en-pacientes-de-edad-avanzada-con-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06052332/efficacy-and-safety-of-conventional-neoadjuvant-therapy-versus-total-neoadjuvant-therapy-in-older-patients-with-locally-advanced-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914766/una-intervencion-informativa-y-de-apoyo-para-pacientes-con-cancer-de-recto-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914766/an-informational-and-supportive-care-intervention-for-patients-with-locally-advanced-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/adg126-y-pembrolizumab-como-tratamiento-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/neoadjuvant-adg126-and-pembrolizumab-in-locally-advanced-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05638542/comparacion-de-la-expresion-de-marcadores-moleculares-relacionados-con-la-carcinogenesis-en-pacientes-con-cancer-de-colon-y-polipos 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05638542/comparison-of-expression-of-carcinogenesis-related-molecular-markers-in-the-patients-with-colon-cancer-and-polyp 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05948826/primer-estudio-en-humanos-de-torl-3-600-en-participantes-con-cancer-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05948826/first-in-human-study-of-torl-3-600-in-participants-with-advanced-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07365592/quimioterapia-neoadyuvante-anticuerpo-anti-pd-1-y-sitagliptina-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365592/neoadjuvant-chemotherapy-anti-pd-1-antibody-and-sitagliptin-for-locally-advanced-pmmr-crc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06068257/fgf19-derivado-del-tumor 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06068257/tumor-derived-fgf19 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06980454/comparacion-de-la-farmacocinetica-en-la-fase-i-de-hlx05-frente-a-erbitux-r-en-hombres-chinos-sanos-seguridad-inmunogenicidad-y-farmacocinetica 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06980454/phase-i-pk-comparison-of-hlx05-vs-erbitux-r-in-healthy-chinese-males-safety-immunogenicity-and-pharmacokinetics 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07549906/iparomlimab-tuvonralimab-neoadyuvante-mas-capeox-frente-a-iparomlimab-tuvonralimab-mas-capeox-y-propranolol-para-el-cancer-colorrectal-localmente-avanzado-pmmr-un-estudio-prospectivo-unicentrico-y 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07549906/neoadjuvant-iparomlimab-tuvonralimab-plus-capeox-versus-iparomlimab-tuvonralimab-plus-capeox-and-propranolol-for-locally-advanced-pmmr-colon-cancer-a-prospective-single-center-multi-cohort-study 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06698757/diferentes-ciclos-de-sintilimab-neoadyuvante-preoperatorio-en-cancer-colorrectal-localmente-avanzado-con-deficiencia-en-la-reparacion-de-errores-de-emparejamiento-alta-inestabilidad-de-microsatelites 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06698757/different-cycles-of-preoperative-neoadjuvant-sintilimab-in-mismatch-repair-deficient-microsatellite-instability-high-locally-advanced-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07363863/patron-de-tratamiento-y-resultados-en-el-carcinoma-rectal-localmente-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363863/pattern-of-treatment-and-outcomes-of-locally-advanced-rectal-carcinoma 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06312982/una-serie-de-casos-de-quimiorradioterapia-neoadyuvante-combinada-con-inmunoterapia-para-el-cancer-de-recto-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06312982/a-series-of-neoadjuvant-chemoradiotherapy-combined-with-immunotherapy-for-locally-advanced-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07372300/electrohipertermia-modulada-en-combinacion-con-terapia-multimodal-para-el-cancer-de-recto-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07372300/modulated-electro-hyperthermia-in-combination-with-multimodal-therapy-for-locally-advanced-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05426005/cadonilimab-para-el-cancer-colorrectal-avanzado-msi-h-dmmr-que-no-responde-al-bloqueo-de-pd-1-pd-l1 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05426005/cadonilimab-for-pd-1-pd-l1-blockade-refractory-msi-h-dmmr-advanced-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06234007/radioterapia-de-corta-duracion-seguida-de-fruquintinib-mas-adebrelimab-y-capox-en-el-tratamiento-neoadyuvante-completo-del-cancer-colorrectal-localmente-avanzado-un-estudio-multicentrico-de-un-solo 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06234007/short-course-radiotherapy-followed-by-fruquintinib-plus-adebrelimab-and-capox-in-the-full-course-neoadjuvant-treatment-of-locally-advanced-rectal-cancer-a-multicenter-single-arm-open-label-study 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402188/estudio-de-seguridad-y-viabilidad-del-sistema-icd-coloseal-tm 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402188/coloseal-tm-icd-system-safety-and-feasibility-study 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06065371/sacituzumab-govitecan-en-combinacion-con-capecitabina-para-el-tratamiento-de-canceres-gastrointestinales-avanzados-despues-de-la-progresion-tras-recibir-la-terapia-estandar 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06065371/sacituzumab-govitecan-in-combination-with-capecitabine-for-advanced-gastrointestinal-cancers-after-progression-on-standard-therapy 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03466424/radioterapia-de-corta-duracion-5-x-6-gy-7-gy-8-gy-seguida-de-quimioterapia-neoadyuvante-para-el-cancer-de-recto-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03466424/short-course-radiotherapy-5x6gy-7gy-8gy-followed-by-neo-adjuvant-chemotherapy-for-locally-advanced-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05877573/toripalimab-en-combinacion-con-quimiorradioterapia-neoadyuvante-como-tratamiento-de-primera-linea-para-el-cancer-de-recto-localmente-avanzado-de-alto-riesgo-y-mss 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05877573/toripalimab-combined-with-neoadjuvant-chemoradiotherapy-as-first-line-treatment-for-locally-advanced-high-risk-mss-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06835179/radioterapia-estereotactica-ablativa-sbrt-combinada-con-capeox-bevacizumab-e-inhibidor-de-pd-1-para-el-tratamiento-del-cancer-colorrectal-metastasico-irresecable-con-mutacion-en-ras-y-de-tipo-mss 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06835179/sbrt-combined-with-capeox-bevacizumab-and-pd-1-inhibitor-for-the-treatment-of-ras-mutant-mss-type-unresectable-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06645301/bgt007-tratamiento-para-tumores-gastrointestinales-recurrentes-o-refractarios 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06645301/bgt007-treatment-for-recurrent-refractory-gastrointestinal-malignancies 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05228431/regimen-terapeutico-sandwich-modificado-para-el-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05228431/modified-sandwich-therapeutic-regimen-for-locally-advanced-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05576480/scrt-penpulimab-en-combinacion-con-capeox-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado-mss 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05576480/scrt-sequential-penpulimab-in-combination-with-capeox-in-the-neoadjuvant-treatment-of-mss-locally-advanced-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04512937/cirugia-asistida-por-navegacion-computarizada-para-el-cancer-colorrectal-localmente-avanzado-y-recurrente 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04512937/computer-navigation-assisted-surgery-for-locally-advanced-and-recurrent-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06903858/toripalimab-mas-celecoxib-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-dmmr-msi-h 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06903858/toripalimab-plus-celecoxib-for-dmmr-msi-h-locally-advanced-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07381400/quimioterapia-neoadyuvante-con-mfolfox6-combinada-con-terapia-anti-pd-1-en-cancer-colorrectal-localmente-avanzado-mss-pmmr-estudio-firm02 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381400/neoadjuvant-mfolfox6-chemotherapy-combined-with-anti-pd-1-therapy-in-mss-pmmr-locally-advanced-rectal-cancer-firm02-study 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06369259/estudio-de-fase-2-abierto-con-avutometinib-inhibidor-de-raf-mek-en-combinacion-con-defactinib-inhibidor-de-fak-y-cetuximab-en-pacientes-con-cancer-colorrectal-avanzado-irresecable-y-resistente-a-los 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06369259/open-label-phase-2-study-of-avutometinib-raf-mek-clamp-in-combination-with-defactinib-fak-inhibitor-and-cetuximab-in-patients-with-unresectable-anti-egfr-refractory-advanced-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06310564/pacientes-con-cancer-colorrectal-oligometastasico-de-riesgo-bajo-e-intermedio-tratados-con-radioterapia-estereotactica-ablativa 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06310564/low-and-intermediate-risk-oligometastatic-colorectal-cancer-patients-treated-with-stereotactic-ablative-radiotherapy 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05005117/abordaje-laparoscopico-para-la-reseccion-de-colon-en-situaciones-de-emergencia 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05005117/laparoscopic-approach-for-emergency-colon-resection 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06753136/electroquimioterapia-ect-en-pacientes-con-tumores-viscerales-primarios-y-o-localizaciones-viscerales-secundarias-de-cualquier-histotipo 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06753136/electrochemotherapy-ect-in-patients-with-primary-visceral-tumors-and-or-secondary-visceral-localizations-of-any-histotype 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06154538/inhibidores-de-los-puntos-de-control-inmunitario-quimioterapia-frente-a-quimioterapia-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06154538/immune-checkpoint-inhibitors-chemotherapy-versus-chemotherapy-in-the-neoadjuvant-treatment-of-locally-advanced-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06879899/vigilancia-guiada-por-la-enfermedad-residual-minima-en-el-cancer-de-recto-localmente-avanzado-de-localizacion-media-o-baja-surveillance-iii 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06879899/mrd-guided-surveillance-in-locally-advanced-mid-low-rectal-cancer-surveillance-iii 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07393048/aplicacion-y-exploracion-de-la-tecnologia-de-deteccion-personalizada-de-ctdna-mrd-para-predecir-la-eficacia-de-la-terapia-neoadyuvante-en-el-cancer-de-recto 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07393048/application-and-exploration-of-personalized-ctdna-mrd-detection-technology-in-predicting-the-efficacy-of-neoadjuvant-therapy-for-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07580339/combinacion-de-dcsz11-con-radioterapia-y-quimioterapia-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580339/combining-dcsz11-with-radiation-and-chemotherapy-as-neoadjuvant-treatment-for-pmmr-locally-advanced-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940388/tratamiento-neoadyuvante-total-con-o-sin-tislelizumab-para-el-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06940388/total-neoadjuvant-treatment-with-or-without-tislelizumab-for-locally-advanced-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07403877/inmunoterapia-neoadyuvante-radioterapia-en-cancer-colorrectal-localmente-avanzado-msi-h-dmmr 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07403877/neoadjuvant-immunotherapy-radiotherapy-in-msi-h-dmmr-locally-advanced-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580027/radioterapia-preoperatoria-adaptativa-concomitante-con-quimioterapia-para-el-adenocarcinoma-rectal-ensayo-adaptativo-de-cancer-rectal-02 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580027/preoperative-adaptive-radiotherapy-concomitant-to-chemotherapy-for-rectal-adenocarcinoma-adaptive-rectal-cancer-trial-02 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06756295/un-estudio-de-fase-i-ii-de-inmunoterapia-con-celulas-t-estimuladas-por-autoantigenos-fragmentados-combinada-con-radioterapia-fast-cr 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06756295/a-phase-i-ii-study-of-fragmented-autoantigen-stimulated-t-cell-immunotherapy-combined-with-radiotherapy-fast-cr 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07587827/estudio-que-evalua-la-seguridad-la-viabilidad-y-la-eficacia-de-la-vacuna-odi-2001-una-inmunoterapia-personalizada-en-pacientes-con-cancer-colorrectal-metastasico-o-localmente-avanzado-o-cancer-de 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07587827/study-evaluating-the-safety-feasibility-and-efficacy-of-odi-2001-vaccine-a-personnalized-immunotherapy-in-patients-with-metastatic-or-locally-advanced-colon-cancer-or-pancreatic-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06682650/implementacion-de-una-herramienta-de-deteccion-del-cancer-colorrectal-en-centros-de-atencion-primaria-de-los-estados-unidos-mejora-de-la-calidad-habitual-10-centros-frente-al-proceso-de-normalizacion 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06682650/implementation-of-a-colorectal-cancer-screening-tool-in-us-primary-care-practices-usual-quality-improvement-10-clinics-vs-normalization-process-theory-participatory-learning-in-action-10-clinics 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06047015/electroforesis-irreversible-nanoknife-r-e-inmunoterapia-para-el-tratamiento-del-cancer-colorrectal-en-estadio-iv 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06047015/irreversible-electroporation-nanoknife-r-and-immunotherapy-for-the-treatment-of-stage-iv-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02917707/analisis-integrativo-de-la-metastasis-hepatica-del-ccrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT02917707/integrative-analysis-of-crc-liver-metastasis 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229340/leflunomida-o-combinacion-de-un-inhibidor-de-mek-e-hidroxicloroquina-para-pacientes-con-mutaciones-en-ras-que-no-responden-al-tratamiento 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229340/leflunomide-or-combination-of-mek-inhibitor-and-hydroxychloroquine-for-refractory-patients-with-ras-mutations 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03525262/terapia-oncologica-para-el-cancer-de-prostata-que-garantiza-la-preservacion-de-los-nervios-y-los-vasos-sanguineos-poten-c 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03525262/prostate-oncologic-therapy-while-ensuring-neurovascular-conservation-poten-c 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06259552/un-estudio-de-spx-303-un-anticuerpo-bispecifico-dirigido-contra-lilrb2-y-pd-l1-en-pacientes-con-tumores-solidos 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06259552/a-study-of-spx-303-a-bispecific-antibody-targeting-lilrb2-and-pd-l1-in-patients-with-solid-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05999812/ensayo-clinico-de-acido-al-trans-retinoico-bevacizumab-y-atezolizumab-en-cancer-colorrectal 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05999812/clinical-trial-of-all-trans-retinoic-acid-bevacizumab-and-atezolizumab-in-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07411599/administracion-combinada-de-terapia-car-nk-dirigida-a-trop2-por-via-intraperitoneal-e-intravenosa-con-la-eliminacion-ko-del-receptor-2-del-tgf-beta-tgfbr2-para-la-carcinomatosis-peritoneal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07411599/dual-administration-of-intraperitoneal-and-intravenous-trop2-directed-car-nk-with-tgf-beta-receptor-2-tgfbr2-knock-out-ko-therapy-for-colorectal-cancer-related-peritoneal-carcinomatosis-a-phase-1-2 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06118762/estudio-clinico-de-fruquintinib-en-combinacion-con-raltitrexed-para-el-tratamiento-del-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06118762/clinical-study-of-fruquintinib-combined-with-raltitrexed-in-the-treatment-of-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05610163/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-el-irinotecan-al-tratamiento-de-quimioterapia-estandar-folfox-tras-la-radioterapia-prolongada-en-pacientes-con-cancer-de-recto-en-estadio-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05610163/testing-the-addition-of-an-anti-cancer-drug-irinotecan-to-the-standard-chemotherapy-treatment-folfox-after-long-course-radiation-therapy-for-advanced-stage-rectal-cancers-to-improve-the-rate-of 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06594692/radioterapia-de-curso-corto-con-preservacion-de-los-ganglios-junto-con-capox-y-sintilimab-para-el-cancer-colorrectal-localmente-avanzado-mss-un-estudio-aleatorizado-prospectivo-y-multicentrico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06594692/node-sparing-short-course-radiation-with-capox-and-sintilimab-for-mss-locally-advanced-colon-cancer-a-randomized-prospective-multicenter-study 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04715633/inhibidores-de-pd-1-combinados-con-inhibidores-de-vegf-para-el-cancer-colorrectal-localmente-avanzado-con-dmmr-msi-h 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04715633/pd-1-inhibitors-combined-with-vegf-inhibitors-for-locally-advanced-dmmr-msi-h-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06229041/tratamiento-neoadyuvante-total-inmunoterapia-para-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-tnti 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229041/total-neoadjuvant-treatment-immunotherapy-for-high-risk-locally-advanced-rectal-cancer-tnti 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04585035/estudio-para-evaluar-d-1553-en-sujetos-con-tumores-solidos 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04585035/study-to-evaluate-d-1553-in-subjects-with-solid-tumors 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06078670/inhibidor-de-parp-cvl218-en-terapia-combinada-para-pacientes-con-tumores-solidos-avanzados 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06078670/parp-inhibitor-cvl218-in-combination-therapy-for-patients-with-advanced-solid-tumors 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03997435/folfoxiri-con-o-sin-intensificacion-para-el-cancer-de-recto 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03997435/folfoxiri-with-or-without-intensification-for-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07118800/estudio-que-evalua-dos-estrategias-de-tratamiento-para-el-cancer-de-recto-en-pacientes-75-anos 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07118800/study-evaluating-two-treatment-strategies-for-rectal-cancer-in-patients-75-years-old 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07407647/dhea-vaginal-para-mejorar-la-salud-vaginal-despues-de-la-radioterapia-en-mujeres-con-cancer-ginecologico-anal-o-de-recto 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07407647/vaginal-dhea-to-improve-vaginal-health-after-radiation-for-women-with-gynecologic-anal-or-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03975049/combinacion-triple-o-regimen-de-doble-farmaco-frente-a-quimiorradiacion-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03975049/triplet-combination-or-doublet-regimen-versus-chemoradiation-as-neoadjuvant-therapy-for-locally-advanced-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07405476/zanidatamab-antes-de-la-cirugia-para-el-tratamiento-del-cancer-colorrectal-her2-positivo-en-pacientes-candidatos-a-tratamiento-con-intencion-curativa 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07405476/zanidatamab-before-surgery-for-the-treatment-of-her2-positive-colon-and-rectal-cancer-in-patients-planned-for-curative-intent-treatment 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06979882/investigacion-de-la-dinamica-de-la-metilacion-multigenica-en-la-vigilancia-de-la-respuesta-al-tratamiento-en-el-carcinoma-intestinal 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06979882/investigating-multigene-methylation-dynamics-in-treatment-response-surveillance-for-intestinal-carcinoma 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07425054/quimiocirradiacion-adaptada-a-la-respuesta-del-adn-tumoral-circulante-de-vph-tratamiento-con-retifanlimab-en-cancer-anal-en-estadio-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07425054/cthpvdna-response-adapted-chemoradiation-retifanlimab-treatment-in-locally-advanced-anal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05148767/terapia-con-irinotecan-basada-en-ugt1a1-para-el-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05148767/ugt1a1-based-irinotecan-therapy-for-locally-advanced-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06373133/shr-8068-en-combinacion-con-adbelizumab-y-bp102-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06373133/shr-8068-combined-with-adbelizumab-and-bp102-in-the-treatment-of-advanced-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05984485/la-eficacia-de-la-cirugia-primaria-de-reseccion-total-del-mesorrecto-tme-frente-a-la-quimioterapia-neoadyuvante-combinada-con-la-cirugia-tme-en-el-cancer-colorrectal-localmente-avanzado-de-bajo-riesgo 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05984485/the-efficacy-of-primary-total-mesorectal-excision-tme-surgery-versus-neoadjuvant-chemotherapy-combined-with-tme-surgery-in-low-risk-locally-advanced-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03875781/estudio-de-no-inferioridad-de-la-quimioterapia-preoperatoria-sin-irradiacion-pelvica-para-el-cancer-de-recto 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03875781/non-inferiority-study-of-preoperative-chemotherapy-without-pelvic-irradiation-for-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07553234/estudio-para-comprender-la-relacion-entre-la-salud-intestinal-y-las-toxicidades-del-tratamiento-hormonal-del-cancer-de-mama 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07553234/study-to-understand-relationship-between-gut-health-and-toxicities-of-hormonal-breast-cancer-treatment 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07656766/sintilimab-mas-acetato-de-gossipol-en-el-cancer-colorrectal-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07656766/sintilimab-plus-gossypol-acetate-in-advanced-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06831981/hipertermia-con-quimiorradioterapia-en-el-cancer-de-recto 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831981/hyperthermia-with-chemoradiotherapy-in-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06690593/caracteristicas-y-relevancia-clinica-de-la-microbiota-intestinal-en-pacientes-con-gammapatia-monoclonal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06690593/characteristics-and-clinical-significance-of-gut-microbiota-in-patients-with-monoclonal-gammopathy 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277842/pd-1-folfoxiri-frente-a-capox-como-terapia-neoadyuvante-total-para-cancer-de-recto-pmmr 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277842/pd-1-folfoxiri-vs-capox-as-total-neoadjuvant-therapy-for-pmmr-low-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06424522/un-programa-de-manejo-intestinal-enema-rectal-retrogrado-para-el-tratamiento-del-sindrome-de-reseccion-anterior-baja-en-pacientes-con-cancer-de-recto 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06424522/a-bowel-management-program-retrograde-rectal-enema-for-the-treatment-of-low-anterior-resection-syndrome-in-rectal-cancer-patients 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06812728/quimioterapia-neoadyuvante-con-folfirinox-y-quimiorradioterapia-preoperatoria-para-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06812728/neoadjuvant-folfirinox-and-preoperative-chemoradiotherapy-for-locally-advanced-rectal-cancer-patients 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07080411/la-eficacia-de-la-radioterapia-adaptativa-en-linea-guiada-por-resonancia-magnetica-para-el-cancer-de-recto-localmente-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07080411/the-efficacy-of-mr-guided-online-adaptive-radiotherapy-for-locally-advanced-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06380101/evaluacion-de-un-alimento-medico-con-restriccion-de-aminoacidos-no-esenciales-neaar-en-combinacion-con-terapia-neoadyuvante-total-para-el-cancer-colorrectal-localmente-avanzado-larc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06380101/evaluating-a-nonessential-amino-acid-restriction-neaar-medical-food-with-total-neoadjuvant-therapy-for-locally-advanced-rectal-cancer-larc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05673772/radioterapia-secuencial-preoperatoria-de-corta-duracion-y-folfox-para-el-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05673772/preoperative-sequential-short-course-radiation-therapy-and-folfox-for-locally-advanced-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06349590/manipulacion-de-la-microbiota-intestinal-mediante-una-dieta-preoperatoria-estandarizada-para-prevenir-la-recurrencia-y-la-metastasis-del-cancer-colorrectal-tras-la-cirugia 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06349590/manipulation-of-the-gut-microbiome-by-a-standardized-preoperative-diet-to-prevent-colorectal-cancer-recurrence-and-metastasis-following-surgery 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05168839/angiografia-por-fluorescencia-con-verde-de-indocianina-intraoperatoria-en-la-cirugia-colorrectal-para-prevenir-las-fugas-anastomoticas 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05168839/intraoperative-indocyanine-green-fluorescence-angiography-in-colorectal-surgery-to-prevent-anastomotic-leakage 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07429760/preparacion-mecanica-del-intestino-con-o-sin-antibioticos-orales-en-la-cirugia-de-cancer-colorrectal-izquierdo 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07429760/mechanical-bowel-preparation-with-or-without-oral-antibiotics-in-left-sided-colorectal-cancer-surgery 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05201430/quimioterapia-neoadyuvante-con-folfoxiri-frente-a-capeox-en-el-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05201430/neoadjuvant-folfoxiri-versus-capeox-chemotherapy-for-local-advanced-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06443671/fruquintinib-neoadyuvante-mas-tislelizumab-en-combinacion-con-mcapeox-frente-a-capeox-para-el-cancer-colorrectal-localmente-avanzado-de-pmmr-mss-intermedio-alto 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06443671/neoadjuvant-fruquintinib-plus-tislelizumab-combined-with-mcapeox-versus-capeox-for-mid-high-pmmr-mss-locally-advanced-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06722534/celecoxib-para-la-prevencion-de-la-progresion-en-el-sindrome-de-peutz-jeghers 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06722534/celecoxib-for-prevention-of-progression-in-peutz-jeghers-syndrome 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06640049/un-estudio-de-dostarlimab-en-participantes-con-cancer-colorrectal-localmente-avanzado-no-tratado-en-china 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06640049/a-study-of-dostarlimab-in-participants-with-untreated-locally-advanced-rectal-cancer-in-china 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07272642/un-estudio-de-fase-i-multicentrico-y-basado-en-imagenes-de-lnth-2403-en-participantes-con-tumores-solidos-localmente-avanzados-o-metastasicos 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07272642/a-phase-1-multicenter-imaging-study-of-lnth-2403-in-participants-with-locally-advanced-or-metastatic-solid-tumors 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07067385/vacuna-de-arnm-personalizada-contra-el-cancer-para-el-tratamiento-de-tumores-solidos-gastrointestinales 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07067385/personalized-mrna-cancer-vaccine-for-gastrointestinal-solid-tumor-treatment 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06542588/radioterapia-de-corta-duracion-seguida-de-quimioterapia-neoadyuvante-hlx07-y-serplulimab-en-el-cancer-colorrectal-localmente-avanzado-larc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06542588/short-course-radiotherapy-followed-by-neoadjuvant-chemotherapy-hlx07and-serplulimab-in-larc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07220174/uso-del-software-gi-genius-tm-xr-en-un-visor-de-realidad-virtual-durante-una-colonoscopia-de-rutina 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07220174/use-of-gi-genius-tm-xr-software-in-virtual-reality-headset-during-routine-colonoscopy 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06911684/radioterapia-mas-iparolimab-y-tuvonalimab-ql1706-regorafenib-y-capox-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr-mss 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06911684/radiotherapy-plus-iparomlimab-and-tuvonralimab-ql1706-regorafenib-and-capox-as-neoadjuvant-therapy-for-pmmr-mss-larc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07001592/inyeccion-intratumoral-it-de-vvdd-hil2-2-rg-1-para-tumores-metastasicos-gastrointestinales-y-peritoneales 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07001592/intra-tumoral-it-injection-of-vvdd-hil2-2-rg-1-for-metastatic-gastrointestinal-and-peritoneal-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05563922/estrategia-de-preservacion-organica-mediante-quimiorradioterapia-neoadyuvante-total-para-el-carcinoma-rectal-bajo 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05563922/organ-preservation-strategy-of-total-neoadjuvant-chemoradiotherapy-for-low-rectal-carcinoma 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07134218/quimiorradioterapia-neoadyuvante-combinada-con-inmunoterapia-y-terapia-antiangiogenica-en-el-tratamiento-del-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134218/neoadjuvant-chemoradiotherapy-combined-with-immunotherapy-and-anti-angiogenesis-in-treating-locally-advanced-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04230759/radioterapia-y-quimioterapia-con-o-sin-durvalumab-para-el-carcinoma-anal-localmente-avanzado-un-ensayo-multicentrico-aleatorizado-de-fase-ii-del-grupo-de-estudio-del-cancer-anal-aleman 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04230759/radiochemotherapy-durvalumab-for-locally-advanced-anal-carcinoma-a-multicenter-randomized-phase-ii-trial-of-the-german-anal-cancer-study-group 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446322/folfiri-y-bevacizumab-con-o-sin-pelareorep-para-el-tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico-con-mutacion-en-ras-y-estable-en-microsatelites 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446322/folfiri-and-bevacizumab-with-or-without-pelareorep-for-second-line-treatment-of-metastatic-ras-mutated-microsatellite-stable-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06613165/explorando-la-duracion-del-tratamiento-con-terapia-neoadyuvante-anti-pd-1-en-el-cancer-colorrectal-en-estadio-ii-iii-con-dmmr 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06613165/exploring-the-treatment-duration-of-pd-1-neoadjuvant-therapy-in-stage-ii-iii-dmmr-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03104439/nivolumab-e-ipilimumab-junto-con-radioterapia-en-cancer-colorrectal-y-de-pancreas-mss-y-msi-h 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03104439/nivolumab-and-ipilimumab-and-radiation-therapy-in-mss-and-msi-high-colorectal-and-pancreatic-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06441565/fruquintinib-solo-o-en-combinacion-con-hai-folfox-para-el-cancer-colorrectal-refractario 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06441565/fruquintinib-with-or-without-hai-folfox-for-refractory-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05674422/estudio-gemcad-reveal-el-adn-tumoral-circulante-como-predictor-de-recurrencia-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05674422/gemcad-reveal-study-circulating-tumor-dna-as-a-predictor-of-relapse-in-patients-with-locally-advanced-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06718543/radioterapia-neoadyuvante-de-corta-duracion-con-o-sin-quimioterapia-y-ak112-en-el-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06718543/neoadjuvant-short-course-radiotherapy-with-or-without-chemotherapy-and-ak112-in-locally-advanced-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05794750/evaluar-la-eficacia-de-la-radioterapia-y-la-quimioterapia-secuencial-asi-como-de-ak104-antes-de-la-cirugia-de-reseccion-mesenterica-total-tme-en-el-cancer-colorrectal-local-ak104-iit-13 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05794750/assess-the-efficacy-of-radiotherapy-and-sequential-chemotherapy-and-ak104-before-tme-surgery-for-local-crc-ak104-iit-13 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07279077/radioterapia-de-baja-dosis-con-conservacion-de-los-ganglios-linfaticos-administrada-de-forma-concurrente-con-quimioterapia-e-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07279077/node-sparing-low-dose-radiotherapy-concurrent-with-chemotherapy-and-pd-1-inhibitor-in-pmmr-mss-high-risk-locally-advanced-colon-cancer-a-prospective-single-arm-phase-ii-trial 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05722288/alimentacion-con-horarios-restringidos-frente-a-asesoramiento-nutricional-para-la-reduccion-de-los-efectos-secundarios-del-tratamiento-con-radioterapia-o-quimiorradioterapia-en-pacientes-con-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05722288/time-restricted-eating-versus-nutritional-counseling-for-the-reduction-of-radiation-or-chemoradiation-tx-side-effects-in-patients-with-prostate-cervical-or-rectal-cancers 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04713618/cambios-en-la-salud-pelvica-la-funcion-sexual-y-la-calidad-de-vida-en-mujeres-con-cancer-pelvico-que-se-someten-a-radioterapia 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04713618/changes-in-pelvic-health-sexual-function-and-quality-of-life-in-women-with-pelvic-cancer-undergoing-radiation-therapy 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04920149/programa-de-prevencion-del-cancer-colorrectal-con-mesalamina-en-el-sindrome-de-lynch 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04920149/mesalamine-for-colorectal-cancer-prevention-program-in-lynch-syndrome 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06550453/seguridad-y-eficacia-de-pembrolizumab-en-combinacion-con-bevacizumab-y-capecitabina-mas-oxaliplatino-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado-con-mutacion-en-ras-braf 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06550453/safety-and-efficacy-of-pembrolizumab-in-combination-with-bevacizumab-capeox-in-the-neoadjuvant-treatment-of-ras-mutated-braf-wild-type-microsatellite-stabilized-locally-advanced-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04215731/mfolfoxiri-neoadyuvante-mas-bevacizumab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-de-alto-riesgo 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04215731/neoadjuvant-mfolfoxiri-plus-bevacizumab-in-patients-with-high-risk-locally-advanced-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04749108/estudio-que-evalua-el-tratamiento-personalizado-del-carcinoma-rectal-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04749108/study-evaluating-the-tailored-management-of-locally-advanced-rectal-carcinoma 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05965531/tratamiento-del-cancer-colorrectal-localmente-avanzado-con-quimioterapia-con-tas-102-mas-radioterapia-neoadyuvante 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05965531/treating-locally-advanced-rectal-cancer-with-tas-102-chemotherapy-plus-neoadjuvant-radiotherapy 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07176182/ensayo-clinico-de-mfolfox-neoadyuvante-mas-alvenor-en-pacientes-con-cancer-colorrectal-localmente-avanzado-larc-con-alta-expresion-de-ywhab 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07176182/clinical-trial-of-neoadjuvant-mfolfox-plus-alvenor-for-larc-patients-with-high-ywhab-expression 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT02983578/danvatirsen-y-durvalumab-en-el-tratamiento-de-pacientes-con-cancer-de-pancreas-avanzado-y-refractario-cancer-de-pulmon-no-microcitico-y-cancer-colorrectal-con-deficiencia-en-la-reparacion-de-errores 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02983578/danvatirsen-and-durvalumab-in-treating-patients-with-advanced-and-refractory-pancreatic-non-small-cell-lung-cancer-and-mismatch-repair-deficient-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06931808/trasplante-de-microbiota-intestinal-radioterapia-combinada-con-quimioterapia-y-sintilimab-en-cancer-colorrectal-avanzado-localizado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06931808/intestinal-microbiota-transplantation-radiochemotherapy-and-sintilimab-in-localized-advanced-colon-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06507371/radioterapia-de-curso-corto-que-preserva-los-ganglios-combinada-con-capox-y-tislelizumab-para-el-cancer-colorrectal-mss 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06507371/node-sparing-short-course-radiation-combined-with-capox-and-tislelizumab-for-mss-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06540261/estudio-de-ono-7913-ono-4538-y-el-tratamiento-estandar-como-terapia-de-primera-linea-en-pacientes-con-cancer-colorrectal 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06540261/the-study-of-ono-7913-ono-4538-and-the-standard-of-care-as-first-line-treatment-in-patients-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07467590/combinacion-de-radioterapia-en-dosis-altas-y-bajas-con-inmunoterapia-y-tki-en-cancer-colorrectal-avanzado-un-estudio-de-fase-ii 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07467590/combination-of-high-and-low-dose-radiotherapy-with-immune-therapy-and-tki-in-advanced-colorectal-cancer-a-phase-ii-study 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06402864/evaluacion-del-contacto-con-rayos-x-y-la-braquiterapia-para-la-preservacion-del-recto-en-el-adenocarcinoma-rectal-de-estadio-intermedio 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402864/evaluation-contact-x-ray-brachytherapy-for-rectal-preservation-in-intermediate-substage-rectal-adenocarcinoma 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06890624/mfolfoxiri-mas-inhibidor-de-pd-1-frente-a-mfolfox6-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06890624/mfolfoxiri-plus-pd-1-inhibitor-vs-mfolfox6-as-neoadjuvant-therapy-for-locally-advanced-colon-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07533227/trasplante-de-la-microbiota-intestinal-para-el-tratamiento-de-la-caquexia-tumoral-avanzada 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07533227/intestinal-microbiota-transplantation-for-treating-advanced-tumor-cachexia 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07596290/yang-et-al-inmunoterapia-dual-anti-pd-1-ctla-4-para-el-cancer-colorrectal-localmente-avanzado-larc 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07596290/yang-et-al-anti-pd-1-ctla-4-dual-immunotherapy-for-larc 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06832917/radioterapia-de-corta-duracion-scrt-seguida-de-6-ciclos-de-cadonilimab-mas-mfolfox6-como-terapia-neoadyuvante-para-pacientes-con-cancer-colorrectal-localmente-avanzado-larc-un-ensayo-multicentrico-de 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06832917/short-course-radiation-scrt-followed-by-6-cycles-of-cadonilimab-plus-mfolfox6-as-neoadjuvant-therapy-for-patients-with-locally-advanced-rectal-cancer-larc-a-multicenter-two-arm-parallel-open-label 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05967143/estudio-observacional-sir-spheres-para-el-tratamiento-de-tumores-hepaticos-irresecables-registro-sirtain 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05967143/observational-sir-spheres-study-for-the-treatment-of-unresectable-liver-tumors-sirtain-registry 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07474025/integracion-de-los-patrones-de-crecimiento-histologico-peritoneal-en-la-toma-de-decisiones-preoperatorias-para-las-metastasis-peritoneales-del-cancer-colorrectal 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07474025/integrating-peritoneal-histological-growth-patterns-into-preoperative-decision-making-for-colorectal-peritoneal-metastses 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04495088/quimioterapia-folfox-preoperatoria-frente-a-quimioterapia-postoperatoria-adaptada-al-riesgo-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04495088/preoperative-folfox-versus-postoperative-risk-adapted-chemotherapy-in-patients-with-locally-advanced-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07478731/tratamiento-neoadyuvante-con-shr-1701-mas-quimiorradioterapia-para-el-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07478731/neoadjuvant-shr-1701-plus-chemoradiotherapy-for-locally-advanced-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06620627/recopilacion-prospectiva-de-muestras-para-permitir-el-desarrollo-del-ensayo-de-deteccion-temprana-del-cancer-de-natera 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06620627/prospective-collection-of-samples-to-enable-the-development-of-natera-screening-assay-for-early-cancer-detection 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT01918527/quimioterapia-neoadyuvante-frente-al-tratamiento-estandar-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT01918527/neoadjuvant-chemotherapy-versus-standard-treatment-in-patients-with-locally-advanced-colon-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616870/estudio-del-papel-predictivo-y-pronostico-de-las-variantes-farmacogeneticas-y-radiogenicas-en-la-respuesta-al-tratamiento-neoadyuvante-con-quimiorradiacion-en-pacientes-con-cancer-colorrectal 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616870/study-of-the-predictive-and-prognostic-role-of-pharmacogenetic-and-radiogenic-variants-on-the-response-to-neoadjuvant-chemoradiation-therapy-in-patients-with-locally-advanced-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03840239/tnt-para-aumentar-la-tasa-de-respuesta-completa-clinica-en-el-cancer-colorrectal-localizado-en-la-parte-distal 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03840239/tnt-to-increase-the-clinical-complete-response-rate-for-distal-larc 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06014944/radioterapia-de-corta-duracion-combinada-con-furoquintinib-y-anticuerpo-monoclonal-anti-pd-1 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06014944/short-course-radiotherapy-combined-with-furoquintinib-and-pd-1-monoclonal-antibody 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06447727/eficacia-y-seguridad-de-las-microesferas-de-90y-en-combinacion-con-folfiri-y-bevacizumab-en-el-tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico-ccrm 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06447727/efficacy-and-safety-of-90y-microsphere-combined-with-folfiri-and-bevacizumab-in-second-line-treatment-of-crlm 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04166604/lonsurf-y-uso-de-g-csf-mantener-la-dosis-e-intensidad-adecuadas-para-optimizar-la-eficacia-del-tratamiento 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04166604/lonsurf-and-g-csf-use-being-on-a-right-dose-intensity-to-optimize-treatment-efficacy 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07486492/utilizando-bacterias-beneficiosas-del-intestino-para-potenciar-el-tratamiento-inmunologico-del-cancer-colorrectal-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07486492/using-healthy-gut-bacteria-to-boost-immune-treatment-for-advanced-bowel-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06563388/radioterapia-ablativa-estereotactica-sabr-para-el-tratamiento-de-pacientes-con-cancer-metastasico-ensayo-id-comet 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563388/stereotactic-ablative-radiotherapy-sabr-for-the-treatment-of-patients-with-metastatic-cancer-id-comet-trial 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224841/desarrollo-de-un-panel-de-biomarcadores-basado-en-la-metilacion-de-la-cfdna-5mc-5hmc-para-predecir-la-eficacia-de-las-terapias-dirigidas-en-el-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224841/development-of-a-cfdna-5mc-5hmc-based-biomarker-panel-to-predict-targeted-therapy-efficacy-in-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06972498/estudio-multicentrico-prospectivo-ivosimab-quimioterapia-como-tratamiento-neoadyuvante-para-metastasis-hepaticas-de-crc-pmmr-mss-resecable 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06972498/a-prospective-multicenter-study-ivosimab-chemotherapy-as-neoadjuvant-for-resectable-pmmr-mss-crc-liver-mets 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07260058/terapia-con-celulas-inmunitarias-para-tumores-solidos-avanzados 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07260058/immune-cell-therapy-for-advanced-solid-tumors 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06493760/un-estudio-de-fase-ii-de-ssgj-707-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06493760/a-phase-2-study-of-ssgj-707-in-metastatic-colorectal-cancer-patients 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03828227/calidad-de-vida-en-pacientes-ancianos-con-cancer-colorrectal-metastasico-que-reciben-terapia-de-primera-linea-basada-en-parametros-geriatricos-simplificados 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03828227/qol-in-mcrc-elderly-patients-receiving-first-line-therapy-based-on-simplified-geriatric-parameters 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07490119/becotatug-vedotina-en-combinacion-con-cetuximab-en-el-tratamiento-en-lineas-posteriores-del-cancer-colorrectal-metastasico-con-ras-tipo-salvaje 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07490119/becotatug-vedotin-combined-with-cetuximab-in-the-later-line-treatment-of-metastatic-ras-wild-type-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05608044/un-estudio-de-botensilimab-y-balstilimab-para-el-tratamiento-del-cancer-colorrectal 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05608044/a-study-of-botensilimab-and-balstilimab-for-the-treatment-of-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05425940/estudio-de-xl092-atezolizumab-frente-a-regorafenib-en-participantes-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05425940/study-of-xl092-atezolizumab-vs-regorafenib-in-participants-with-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06449989/comparacion-de-la-concordancia-molecular-genetica-del-tumor-primario-y-las-metastasis-cerebrales-del-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449989/comparison-of-molecular-genetic-concordance-of-the-primary-tumor-and-brain-metastases-of-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06826092/metformina-para-el-tratamiento-de-pacientes-con-mcrc-que-reciben-folfiri-mas-terapia-dirigida 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06826092/metformin-for-the-treatment-of-mcrc-patients-undergoing-folfiri-plus-target-therapy 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06090994/prevencion-de-la-recurrencia-y-la-metastasis-del-cancer-colorrectal-mediante-la-comparacion-de-huaier-con-la-monoterapia-con-capecitabina 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06090994/prevention-of-recurrence-and-metastasis-of-colorectal-cancer-by-comparing-huaier-with-capecitabine-monotherapy 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07114601/un-estudio-de-ly4257496-en-participantes-con-cancer-omniray 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07114601/a-study-of-ly4257496-in-participants-with-cancer-omniray 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06011772/terapia-antigeno-egf-cimavax-egf-en-combinacion-con-la-terapia-estandar-para-el-cancer-colorrectal-metastasico-con-mutaciones-ras-y-braf-no-detectables 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06011772/egf-depleting-therapy-cimavax-egf-in-combination-with-standard-therapy-for-ras-and-braf-wild-type-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07030257/estudio-de-cp-383-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07030257/study-of-cp-383-in-patients-with-advanced-or-metastatic-solid-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503808/un-estudio-de-ide034-en-participantes-adultos-con-tumores-solidos-avanzados-localmente-o-metastasicos 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503808/a-study-of-ide034-in-adult-participants-with-locally-advanced-metastatic-solid-tumors-types 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05167448/un-estudio-de-es104-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167448/a-study-of-es104-in-patients-with-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503756/js212-terapias-combinadas-en-el-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503756/js212-combination-therapies-in-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07621497/folfox8-frente-a-mfolfox6-con-bevacizumab-o-cetuximab-para-el-cancer-colorrectal-metastasico-irresecable-en-primera-linea-fase-ii 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07621497/folfox8-versus-mfolfox6-with-bevacizumab-or-cetuximab-for-first-line-unresectable-metastatic-colorectal-cancer-phase-ii 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03493048/cetuximab-mas-folfoxiri-frente-a-cetuximab-mas-folfox-en-el-tratamiento-del-cancer-colorrectal-metastasico-crclm 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03493048/cetuximab-plus-folfoxiri-vs-cetuximab-plus-folfox-for-crclm 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224724/deteccion-de-metastasis-extrahepaticas-derivadas-de-exosomas-mediante-biopsia-liquida-en-metastasis-hepaticas-del-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224724/exosome-derived-extrahepatic-metastasis-detection-by-liquid-biopsy-in-colorectal-cancer-liver-metastases 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04959604/mapeo-de-los-ganglios-linfaticos-mediante-un-tinte-fluorescente-en-el-cancer-de-colon 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04959604/lymph-node-mapping-via-flourescent-dye-in-colon-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07621159/un-estudio-de-fase-ib-ii-de-hdm2017-en-combinacion-con-el-tratamiento-estandar-en-el-cancer-colorrectal-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07621159/a-phase-ib-ii-study-of-hdm2017-in-combination-with-standard-of-care-in-advanced-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06258525/same-en-la-prevencion-de-la-lesion-hepatica-asociada-a-oxaliplatino 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06258525/same-in-prevention-of-oxaliplatin-associated-liver-injury 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06440005/un-estudio-para-evaluar-la-seguridad-la-tolerabilidad-y-la-actividad-preliminar-de-agx101-en-participantes-con-tumores-solidos-avanzados 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440005/a-study-to-evaluate-safety-tolerability-and-preliminary-activity-of-agx101-in-participants-with-advanced-solid-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06589440/estudio-de-fase-ii-de-sr-8541a-en-combinacion-con-botensilimab-y-balstilimab-en-sujetos-con-cancer-colorrectal-metastasico-resistente-al-tratamiento-y-con-estabilidad-de-microsatelites-mss-crc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06589440/phase-2-study-of-sr-8541a-in-combination-with-botensilimab-and-balstilimab-in-subjects-with-refractory-metastatic-microsatellite-stable-colorectal-cancer-mss-crc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04564898/trifluridina-tipiracil-en-combinacion-con-capecitabina-y-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04564898/trifluridine-tipiracil-in-combination-with-capecitabine-and-bevacizumab-in-metastatic-colorectal-cancer-patients 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06750094/un-estudio-de-amivantamab-y-folfiri-frente-a-cetuximab-bevacizumab-y-folfiri-en-participantes-con-cancer-colorrectal-kras-nras-y-braf-de-tipo-salvaje-que-previamente-han-recibido-quimioterapia 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06750094/a-study-of-amivantamab-and-folfiri-versus-cetuximab-bevacizumab-and-folfiri-in-participants-with-kras-nras-and-braf-wild-type-colorectal-cancer-who-have-previously-received-chemotherapy 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04584008/evaluacion-de-agentes-dirigidos-en-canceres-digestivos-en-china-basada-en-las-caracteristicas-moleculares 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04584008/targeted-agent-evaluation-in-digestive-cancers-in-china-based-on-molecular-characteristics 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06287723/estudio-frances-sobre-la-evaluacion-de-la-enfermedad-residual-minima-mediante-biopsias-liquidas-en-pacientes-con-cancer-colorrectal-y-metastasis-hepaticas-french-mrd-crlm 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06287723/french-assessment-of-mrd-by-liquid-biopsies-in-colorectal-with-liver-metastasis-patients-french-mrd-crlm 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06749015/un-estudio-sobre-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-mutacion-brafv600e 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06749015/a-study-on-treatment-for-patients-with-brafv600e-mutant-metastatic-colorectal-cancer-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06184698/irinotecan-liposomal-y-leucovorina-5-fluorouracilo-mas-bevacizumab-en-el-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06184698/liposomal-irinotecan-and-leucovorin-5-fluorouracil-plus-bevacizumab-in-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03494946/trasplante-hepatico-en-comparacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03494946/liver-transplantation-compared-to-chemotherapy-in-patients-with-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07631884/estudio-exploratorio-sobre-la-eficacia-y-la-seguridad-del-trastuzumab-rezetecan-en-el-tratamiento-de-tumores-solidos-avanzados-con-expresion-de-her2 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07631884/exploratory-study-on-the-efficacy-and-safety-of-trastuzumab-rezetecan-in-the-treatment-of-her2-expressiong-advanced-solid-tumor 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06255379/estudio-de-fruquintinib-en-combinacion-con-tegafur-gimeracil-y-oteracil-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06255379/study-of-fruquintinib-combined-with-tegafur-gimeracil-oteracil-in-patients-with-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07042685/ensayo-clinico-de-una-terapia-basada-en-5-fluorouracilo-5-fu-en-combinacion-con-fruquintinib-en-pacientes-con-cancer-colorrectal-localmente-avanzado-irresecable-o-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07042685/trial-of-5-fluorouracil-5fu-based-therapy-in-combination-with-fruquintinib-in-patients-with-locally-advanced-unresectable-or-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035886/un-estudio-para-monitorizar-el-tratamiento-con-fruzaqla-en-adultos-con-cancer-colorrectal-metastasico-mcrc-en-corea-del-sur 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035886/a-study-to-monitor-the-fruzaqla-treatment-of-adults-with-metastatic-colorectal-cancer-mcrc-in-south-korea 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05093907/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-bey1107-en-combinacion-con-capecitabina-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05093907/a-study-to-evaluate-safety-and-efficacy-of-bey1107-in-combination-with-capecitabine-in-patients-with-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06646341/emvi-como-factor-determinante-de-la-metastasis-en-el-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06646341/emvi-as-a-determinant-of-metastasis-in-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07071844/between-bevacizumab-y-trifluridina-tipiracil-administrados-cada-dos-semanas-para-reducir-la-neutropenia-de-grado-3-4-en-pacientes-con-mcrc 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07071844/between-biweekly-bevacizumab-trifluridine-tipiracil-to-reduce-grade-3-4-neutropenia-in-mcrc-patients 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05803382/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-zen003694-al-tratamiento-de-quimioterapia-habitual-capecitabina-para-canceres-metastasicos-o-irresecables 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05803382/testing-the-addition-of-an-anti-cancer-drug-zen003694-to-the-usual-chemotherapy-treatment-capecitabine-for-metastatic-or-unresectable-cancers 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06794931/estudio-sobre-el-impacto-de-una-dieta-mediterranea-modificada-en-pacientes-con-cancer-colorrectal-que-reciben-tratamiento-oncologico-activo 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06794931/study-on-the-impact-of-a-modified-mediterranean-diet-in-patients-with-colorectal-cancer-undergoing-active-medical-oncology-treatment 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05057052/crioablacion-combinada-con-sintilimab-mas-regorafenib-en-metastasis-hepaticas-de-cancer-colorrectal-previamente-tratadas 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05057052/cryoablation-combined-with-sintilimab-plus-regorafenib-in-previously-treated-colorectal-cancer-liver-metastasis 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04730544/dos-esquemas-de-tratamiento-combinados-con-nivolumab-e-ipilimumab-en-pacientes-con-mcrc-dmmr-y-o-msi 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04730544/two-combination-treatment-regimens-of-nivolumab-and-ipilimumab-in-patients-with-dmmr-and-or-msi-mcrc 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05201352/evaluacion-de-la-eficacia-de-trifluridina-tipiracil-mas-un-anticuerpo-humano-verdadero-anti-il-1-frente-a-trifluridina-tipiracil-mas-placebo-en-pacientes-con-cancer-colorrectal-metastasico-despues 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05201352/evaluation-of-efficacy-of-trifluridine-tipiracil-plus-an-anti-il-1-true-human-antibody-versus-trifluridine-tipiracil-plus-placebo-in-metastatic-colorectal-cancer-patients-after-failure-of-oxaliplatin 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06012734/lb-100-inhibidor-de-pp2a-y-atezolizumab-inhibidor-de-pd-l1-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06012734/lb-100-pp2a-inhibitor-and-atezolizumab-pd-l1-inhibitor-in-metastatic-colorectal-cancer-patients 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT02595931/m6620-e-hidrocloruro-de-irinotecan-en-el-tratamiento-de-pacientes-con-tumores-solidos-metastasicos-o-que-no-pueden-ser-extirpados-mediante-cirugia 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02595931/m6620-and-irinotecan-hydrochloride-in-treating-patients-with-solid-tumors-that-are-metastatic-or-cannot-be-removed-by-surgery 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04754672/entrenamiento-de-aptitud-aerobica-o-de-masa-muscular-para-mejorar-el-resultado-en-el-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04754672/aerobic-fitness-or-muscle-mass-training-to-improve-colorectal-cancer-outcome 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07536113/evaluacion-de-la-eficacia-y-la-seguridad-de-la-seleccion-basada-en-el-adn-tumoral-circulante-ctdna-para-un-nuevo-tratamiento-con-anti-egfr-en-una-cohorte-de-pacientes-con-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07536113/assessing-the-efficacy-and-safety-of-ctdna-driven-selection-for-anti-egfr-retreatment-in-a-real-world-metastatic-colorectal-cancer-patients-cohort-the-realchallenge-study 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT02394834/un-estudio-exploratorio-de-la-sensibilidad-al-tratamiento-y-los-factores-pronosticos-en-un-estudio-de-eficacia-y-seguridad-de-mfolfox6-bevacizumab-frente-a-mfolfox6-panitumumab-en-pacientes-con 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02394834/an-exploratory-study-of-treatment-sensitivity-and-prognostic-factors-in-a-efficacy-and-safety-study-of-mfolfox6-bevacizumab-versus-mfolfox6-panitumumab-therapy-in-patients-with-chemotherapy-naive 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04222413/metarrestin-ml-246-en-pacientes-con-tumores-solidos-metastasicos 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04222413/metarrestin-ml-246-in-subjects-with-metastatic-solid-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462613/regorafenib-combinado-con-quimioterapias-a-dosis-bajas-y-aspirina-seguido-de-quimioterapias-estandar-en-el-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462613/regorafenib-with-low-dose-chemotherapies-and-aspirin-followed-by-standard-chemotherapies-in-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04562727/ablacion-por-microondas-combinada-con-quimioterapia-para-metastasis-hepaticas-de-cancer-colorrectal-un-estudio-de-cohortes-multicentrico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04562727/microwave-ablation-combined-with-chemotherapy-for-colorectal-liver-metastases-a-multicenter-cohort-study 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06849362/estudio-retrospectivo-multicentrico-sobre-la-optimizacion-de-las-estrategias-de-inmunoterapia-combinada-en-el-cancer-colorrectal-avanzado-mss-msi-l-pmmr 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06849362/multicenter-retrospective-study-on-optimizing-combination-immunotherapy-strategies-in-mss-msi-l-pmmr-advanced-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04894370/combinacion-de-spartalizumab-mdcf-y-radioterapia-en-pacientes-con-carcinoma-anal-de-celulas-escamosas-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04894370/combination-of-spartalizumab-mdcf-and-radiotherapy-in-patients-with-metastatic-squamous-cell-anal-carcinoma 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07154173/analisis-exhaustivo-de-las-caracteristicas-de-la-microbiota-intestinal-en-el-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07154173/comprehensive-analysis-of-gut-microbiota-signatures-in-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06974110/estudio-de-moma-341-administrado-por-via-oral-en-participantes-con-tumores-solidos-avanzados-o-metastasicos 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06974110/study-of-orally-administered-moma-341-in-participants-with-advanced-or-metastatic-solid-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06601075/el-papel-del-pet-tc-con-18f-fdg-y-68ga-fapi-en-el-diagnostico-y-la-evaluacion-de-la-eficacia-del-cancer-colorrectal-avanzado-metastasis-peritoneal-con-o-sin-otras-metastasis 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06601075/the-role-of-18f-fdg-and-68ga-fapi-pet-ct-in-the-diagnosis-and-the-efficacy-evaluation-of-advanced-colorectal-cancer-peritoneal-metastasis-with-without-other-metastases 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07543744/un-estudio-comparativo-de-la-farmacocinetica-la-seguridad-y-la-inmunogenicidad-de-rph-030-y-vectibix-r-en-pacientes-con-cancer-colorrectal-metastasico-con-ras-de-tipo-salvaje-como-terapia-de-primera 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07543744/a-comparative-study-of-pharmacokinetics-safety-and-immunogenicity-of-rph-030-and-vectibix-r-in-patients-with-metastatic-colorectal-cancer-with-wild-type-ras-as-first-line-therapy-in-combination-with 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05447611/papel-de-la-empatia-en-los-resultados-del-tratamiento-curativo-del-cancer-colorrectal-no-metastasico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05447611/role-of-empathy-in-curative-treatment-outcomes-of-non-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04940546/seguridad-del-tratamiento-neoadyuvante-con-sintilimab-xelox-bevacizumab-en-pacientes-con-metastasis-colorrectales-mcrlm-con-pmmr-mss 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04940546/neoadjuvant-safety-of-sintilimab-xelox-bevacizumab-in-pmmr-mss-crlm-patients 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07361003/un-estudio-de-fase-ib-iii-de-suvemcitug-mas-ftd-tpi-en-participantes-con-cancer-colorrectal-metastasico-refractario 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07361003/a-phase-ib-iii-study-of-suvemcitug-plus-ftd-tpi-in-participants-with-refractory-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07261709/trifluridina-tipiracil-mas-fruquintinib-frente-a-trifluridina-tipiracil-mas-bevacizumab-en-cancer-colorrectal-metastasico-refractario-un-ensayo-aleatorizado-controlado-de-etiqueta-abierta-de-no 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07261709/trifluridine-tipiracil-plus-fruquintinib-vs-trifluridine-tipiracil-plus-bevacizumab-in-refractory-metastatic-colorectal-cancer-a-randomized-controlled-open-label-non-inferiority-trial 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04587128/terapia-anti-egfr-en-lineas-tempranas-para-facilitar-el-retratamiento-en-pacientes-seleccionados-con-mcrc 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04587128/early-line-anti-egfr-therapy-to-facilitate-retreatment-for-select-patients-with-mcrc 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07551778/terapia-con-celulas-nk-alogenicas-combinada-con-el-tratamiento-de-mantenimiento-estandar-en-tumores-solidos-avanzados 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07551778/allogeneic-nk-cell-therapy-combined-with-standard-maintenance-treatment-in-advanced-solid-tumors 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06643793/evaluacion-del-liposoma-de-irinotecan-ii-en-combinacion-con-5-fu-lv-y-bevacizumab-para-el-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06643793/evaluation-of-irinotecan-liposome-ii-combined-with-5-fu-lv-and-bevacizumab-for-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07085169/trifluridina-tipiracil-a-dosis-bajas-con-bevacizumab-en-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07085169/low-dose-trifluridine-tipiracil-with-bevacizumab-in-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06423937/fruquintinib-mas-camrelizumab-y-haic-en-el-tratamiento-del-cancer-colorrectal-avanzado-no-msi-h 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06423937/fruquintinib-plus-camrelizumab-and-haic-in-the-treatment-of-non-msi-h-advanced-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06698146/metastasis-colorrectal-en-el-higado-extraccion-con-trasplante-auxiliar-y-reseccion-tardia 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06698146/colorectal-metastasis-to-liver-extraction-with-auxiliary-transplant-and-delayed-resection 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07362836/fruquintinib-frente-a-bevacizumab-mas-quimioterapia-en-el-tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico-con-mutacion-en-los-genes-ras-fru-ras 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07362836/fruquintinib-versus-bevacizumab-plus-chemotherapy-in-second-line-ras-mutant-metastatic-colorectal-cancer-fru-ras 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06403709/irinotecan-tas-102-mas-bevacizumab-como-terapia-de-tercera-linea-o-posterior-en-pacientes-con-mcrc 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06403709/irinotecan-tas-102-plus-bevacizumab-as-a-third-line-or-beyond-therapy-in-mcrc-patients 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06485713/eficacia-y-seguridad-de-la-combinacion-de-trifluridina-tipiracil-con-fufuquitinib-como-tratamiento-de-tercera-linea-para-el-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06485713/efficacy-and-safety-of-trifluridine-tipiracil-combined-with-fufuquitinib-for-third-line-treatment-of-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05487248/un-estudio-de-los-cambios-en-el-ctdna-durante-el-tratamiento-en-pacientes-con-cancer-colorrectal-resistente-a-la-quimioterapia 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05487248/a-study-of-on-treatment-ctdna-changes-in-chemo-refractory-colorectal-cancer-patients 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07044362/histotripsia-mas-quimioterapia-frente-a-quimioterapia-sola-en-metastasis-hepaticas-avanzadas-de-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044362/histotripsy-plus-chemotherapy-vs-chemotherapy-alone-for-advanced-colorectal-liver-metastasis 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07559760/nueva-terapia-combinada-de-segunda-linea-para-el-cancer-colorrectal-metastasico-mss 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07559760/new-second-line-combo-therapy-for-mss-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07124858/estudio-prospectivo-multicentrico-a-nivel-nacional-para-evaluar-los-factores-pronosticos-relacionados-con-la-eficacia-del-tratamiento-con-fruquintinib-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07124858/prospective-national-cohort-evaluating-prognostic-factors-for-efficacy-of-fruquintinib-treatment-in-patients-with-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06192680/irinotecano-liposomal-y-capecitabina-mas-bevacizumab-como-terapia-de-segunda-linea-en-el-cancer-colorrectal-metastasico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06192680/liposomal-irinotecan-and-capecitabine-plus-bevacizumab-as-second-line-therapy-in-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06356584/fruquintinib-en-combinacion-con-sintilimab-radioterapia-para-el-tratamiento-en-tercera-linea-del-cancer-colorrectal-con-metastasis-hepaticas 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06356584/fruquintinib-combined-with-sintilimab-radiotherapy-for-third-line-treatment-of-colorectal-cancer-with-liver-metastases 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03038568/evaluacion-del-impacto-de-las-variaciones-normales-en-las-tomografias-computarizadas-tc-en-su-interpretacion 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03038568/assessing-how-normal-variations-in-ct-scanning-affects-its-interpretation 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05884723/dieta-cetogenica-preoperatoria-para-la-reduccion-de-la-esteatosis-hepatica 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05884723/preoperative-ketogenic-diet-for-reduction-of-hepatic-steatosis 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05991102/tratamiento-con-campos-electromagneticos-de-radiofrecuencia-de-modulacion-de-amplitud-combinado-con-tas-102-lonsurf-y-bevacizumab-en-el-cancer-colorrectal-metastasico-refractario 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05991102/amplitude-modulated-radiofrequency-electromagnetic-field-treatment-combined-with-tas-102-lonsurf-and-bevacizumab-in-refractory-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04845490/estudio-comparativo-de-mitomicina-y-lobaplatino-en-pacientes-con-cancer-colorrectal-avanzado-sometidos-a-cirugia-radical-combinada-con-quimioterapia-intraperitoneal-hiperermica 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04845490/comparative-study-of-mitomycin-and-lobaplatin-in-advanced-colorectal-cancer-patients-with-radical-surgery-combined-with-hyperthermic-intraperitoneal-chemotherapy 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05360277/tratamiento-de-mantenimiento-con-tislelizumab-y-capecitabina-para-el-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05360277/maintenance-tislelizumab-capecitabine-to-treat-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06540326/estudio-clinico-del-tratamiento-de-segunda-linea-en-el-cancer-colorrectal-avanzado-con-quimioterapia-con-bevacizumab-o-cetuximab 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06540326/clinical-study-of-second-line-treatment-in-advanced-colorectal-cancer-with-chemotherapy-with-bevacizumab-or-cetuximab 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03428477/epa-para-el-ensayo-clinico-sobre-metastasis-2 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03428477/epa-for-metastasis-trial-2 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06833866/ensayo-de-fase-i-de-una-terapia-basada-en-5-fluorouracilo-5fu-en-combinacion-con-hidroxitirosol-ht-en-pacientes-con-cancer-colorrectal-avanzado-o-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06833866/phase-i-trial-of-5-fluorouracil-5fu-based-therapy-in-combination-with-hydroxytyrosol-ht-in-patients-with-advanced-or-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06456515/regorafenib-y-sintilimab-en-combinacion-con-electroacupuntura-en-crc-mss 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06456515/regorafenib-and-sintilimab-in-combination-with-electroacupuncture-in-mss-crc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05970302/xelox-bevacizumab-tislelizumab-para-el-tratamiento-de-primera-linea-del-mcrc-con-mss-pmmr-y-mutacion-en-ras 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05970302/xelox-bev-tislelizumab-for-first-line-treatment-of-mss-pmmr-ras-mutated-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07398326/anlotinib-en-combinacion-con-sintilimab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-avanzado-excluyendo-las-metastasis-hepaticas 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07398326/anlotinib-combined-with-sintilimab-as-first-line-treatment-for-advanced-non-liver-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT02671435/un-estudio-de-durvalumab-medi4736-y-monalizumab-en-tumores-solidos 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02671435/a-study-of-durvalumab-medi4736-and-monalizumab-in-solid-tumors 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02885753/oxaliplatino-sistemico-o-quimioterapia-intraarterial-combinada-con-lv5fu2-irinotecan-y-una-terapia-dirigida-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-restringido-al-higado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT02885753/systemic-oxaliplatin-or-intra-arterial-chemotherapy-combined-with-lv5fu2-irinotecan-and-an-target-therapy-in-first-line-treatment-of-metastatic-colorectal-cancer-restricted-to-the-liver 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714357/acido-valproico-para-potenciar-la-eficacia-del-tratamiento-anti-egfr-y-prevenir-revertir-la-resistencia-en-el-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714357/valproic-acid-to-potentiate-anti-egfr-treatment-efficacy-and-prevent-revert-resistance-in-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03364621/analisis-genomico-exhaustivo-de-pacientes-con-cancer-colorrectal-y-metastasis-hepaticas-aisladas-para-comprender-la-respuesta-y-la-resistencia-a-la-terapia-contra-el-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03364621/comprehensive-genomic-profiling-of-colorectal-cancer-patients-with-isolated-liver-metastases-to-understand-response-resistance-to-cancer-therapy 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05141721/un-estudio-de-una-vacuna-neoantigenica-especifica-para-el-paciente-en-combinacion-con-el-bloqueo-de-los-puntos-de-control-inmunitario-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05141721/a-study-of-a-patient-specific-neoantigen-vaccine-in-combination-with-immune-checkpoint-blockade-for-patients-with-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07583381/un-estudio-prospectivo-sobre-una-tecnologia-de-estimacion-de-la-presion-asistida-por-subarmonicos-para-la-prediccion-temprana-de-la-respuesta-a-la-terapia-sistemica-en-metastasis-hepaticas-del-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07583381/a-prospective-study-of-a-subharmonic-aided-pressure-estimate-technology-for-early-prediction-of-response-to-systemic-therapy-in-colorectal-cancer-liver-metastases 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07044921/estudio-clinico-de-un-tratamiento-combinado-basado-en-irinotecan-liposomal-ii-para-el-cancer-colorrectal-resistente-al-irinotecan 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044921/clinical-study-of-irinotecan-liposome-ii-based-combination-treatment-for-irinotecan-resistant-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03350126/relevancia-de-la-evaluacion-irecist-para-la-tasa-de-respuesta-global-dcr-en-pacientes-con-cancer-colorrectal-metastasico-mmr-msi-tratados-con-nivolumab-e-ipilimumab 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03350126/irecist-evaluation-s-relevance-for-dcr-in-mmr-msi-metastatic-colorectal-cancer-patients-on-nivolumab-and-ipilimumab 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05354674/firma-de-aprendizaje-profundo-multimodal-para-la-evaluacion-de-la-respuesta-al-bevacizumab-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05354674/multimodal-deep-learning-signature-for-evaluation-of-response-to-bevacizumab-in-patient-with-colorectal-cancer-liver-metastasis 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277322/dupilumab-y-toripalimab-como-tratamiento-neoadyuvante-en-sujetos-con-crc-mss-y-metastasis-hepaticas-resecables 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277322/neoadjuvant-dupilumab-and-toripalimab-in-mss-crc-subjects-with-resectable-liver-metastases 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02906943/evaluacion-de-acidos-nucleicos-dirigida-a-tumores-en-toda-la-provincia-de-ontario 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT02906943/ontario-wide-cancer-targeted-nucleic-acid-evaluation 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04491929/terapia-de-radiacion-interna-selectiva-con-microesferas-de-resina-de-90y-para-metastasis-hepaticas-de-cancer-colorrectal-refractario 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04491929/selective-internal-radiation-therapy-with-90y-resin-micropheres-for-refractory-colorectal-cancer-liver-metastases 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04670679/un-estudio-de-escalada-de-dosis-expansion-de-eras-601-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04670679/a-dose-escalation-expansion-study-of-eras-601-in-patients-with-advanced-or-metastatic-solid-tumors 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06824064/evaluacion-de-rbs2418-en-pacientes-con-cancer-colorrectal-avanzado-metastasico-y-en-progresion 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06824064/evaluation-of-rbs2418-in-patients-with-advanced-metastatic-and-progressive-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06978400/un-estudio-de-dabrafenib-mas-cetuximab-panitumumab-con-folfox-en-la-primera-linea-de-tratamiento-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06978400/a-study-of-dabrafenib-plus-cetuximab-panitumumab-with-folfox-in-the-first-line-of-therapy-in-people-with-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07198958/registro-de-eventos-adversos-inmunologicos-en-pacientes-onco-hematologicos-tratados-con-inmunoterapia 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07198958/immune-adverse-events-registry-in-onco-hematologic-patients-treated-with-immunotherapy 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05655780/el-papel-del-perfil-molecular-tumoral-cms-el-genotipo-ugt1a1-y-la-actividad-de-la-beta-glucuronidasa-de-la-microbiota-intestinal-en-la-eficacia-del-tratamiento-la-toxicidad-la-supervivencia-y-la 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05655780/the-role-of-the-tumor-molecular-profile-cms-ugt1a1-genotype-and-beta-glucuronidase-activity-of-the-intestinal-microbiota-for-treatment-efficiency-toxicity-survival-and-quality-of-life-in-patients 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853496/estudio-de-un-inhibidor-de-la-tanquirasa-el-rk-582-en-pacientes-con-cancer-colorrectal-metastasico-irresecable 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853496/study-of-a-tankyrase-inhibitor-rk-582-for-patients-with-unresectable-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06746545/un-estudio-clinico-prospectivo-de-etiqueta-abierta-de-un-solo-brazo-de-fase-ii-para-evaluar-la-combinacion-de-fruquintinib-con-s-1-en-el-tratamiento-del-cancer-colorrectal-metastasico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06746545/a-prospective-open-label-single-arm-phase-ii-clinical-study-of-fruquintinib-combined-with-s-1-for-the-treatment-of-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07430527/revision-del-protocolo-para-el-tratamiento-del-cancer-colorrectal-en-atencion-secundaria 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07430527/secondary-care-colorectal-cancer-pathway-review 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT00569127/octreotido-acetato-e-interferon-alfa-2b-recombinante-o-bevacizumab-en-el-tratamiento-de-pacientes-con-tumor-neuroendocrino-metastasico-o-localmente-avanzado-de-alto-riesgo 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT00569127/octreotide-acetate-and-recombinant-interferon-alfa-2b-or-bevacizumab-in-treating-patients-with-metastatic-or-locally-advanced-high-risk-neuroendocrine-tumor 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02314169/nivolumab-con-o-sin-ipilimumab-en-el-tratamiento-de-pacientes-con-cancer-metastasico-del-conducto-anal-refractario 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02314169/nivolumab-with-or-without-ipilimumab-in-treating-patients-with-refractory-metastatic-anal-canal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02888743/durvalumab-y-tremelimumab-con-o-sin-radioterapia-en-dosis-altas-o-bajas-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-o-cancer-de-pulmon-no-microcitico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02888743/durvalumab-and-tremelimumab-with-or-without-high-or-low-dose-radiation-therapy-in-treating-patients-with-metastatic-colorectal-or-non-small-cell-lung-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06642844/quimioterapia-basada-en-bevacizumab-adaptada-a-la-farmacocinetica-del-bevacizumab-en-el-tratamiento-de-primera-linea 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06642844/bevacizumab-based-chemotherapy-adapted-to-bevacizumab-pharmacokinetics-in-1st-line-treatment 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/un-estudio-de-mrg007-arr-217-en-pacientes-con-tumores-solidos-avanzados 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/a-study-of-mrg007-arr-217-in-patients-with-advanced-solid-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277270/un-estudio-de-gsk5764227-en-combinacion-con-el-tratamiento-estandar-soc-u-otros-agentes-en-participantes-con-tumores-solidos-avanzados 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277270/a-study-of-gsk5764227-in-combination-with-standard-of-care-soc-or-other-agents-in-participants-with-advanced-solid-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05319314/gcc19cart-para-pacientes-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05319314/lyl273-for-patients-with-relapsed-or-refractory-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07591597/un-ensayo-clinico-multicentrico-de-fase-ib-ii-para-evaluar-la-eficacia-y-la-seguridad-de-la-terapia-combinada-concurrente-de-s-531011-mas-fruquintinib-o-s-531011-mas-fruquintinib-mas-pembrolizumab-en 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07591597/a-multicenter-phase-ib-ii-clinical-trial-to-evaluate-the-efficacy-and-safety-of-concurrent-combination-therapy-of-s-531011-plus-fruquintinib-or-s-531011-plus-fruquintinib-plus-pembrolizumab-in 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07435584/everolimus-en-cancer-colorrectal-metastasico-con-deficiencia-de-cdk12-ever-recode 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07435584/everolimus-in-cdk12-deficient-metastatic-colorectal-cancer-ever-recode 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07204574/estudio-de-fase-1b-iia-abierto-de-escalada-y-expansion-de-dosis-para-evaluar-la-seguridad-la-tolerabilidad-y-la-eficacia-preliminar-de-la-combinacion-de-hcb101-cetuximab-bevacizumab-y-folfox-folfiri 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07204574/the-phase-1b-iia-open-label-dose-escalation-and-dose-expansion-to-evaluate-safety-tolerability-and-preliminary-efficacy-of-the-combination-of-hcb101-cetuximab-bevacizumab-and-folfox-folfiri-in 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06275958/estudio-de-dosis-quimioterapia-con-dosis-reducidas-en-primera-linea-en-pacientes-de-edad-avanzada-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06275958/dosage-study-upfront-dose-reduced-chemotherapy-in-older-patients-with-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06883084/relevancia-clinica-de-la-regresion-patologica-en-los-ganglios-linfaticos-en-el-cancer-colorrectal-localmente-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06883084/clinical-relevance-of-pathologic-regression-in-lymph-node-for-locally-advanced-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05240950/celulas-car-t-anti-cea-para-el-tratamiento-de-metastasis-hepaticas-de-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05240950/anti-cea-car-t-cells-to-treat-colorectal-liver-metastases 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07453875/ldrt-quimioterapia-inmunologica-secuencial-con-nips-para-metastasis-peritoneales-de-cancer-gastrico-y-colorrectal 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07453875/ldrt-sequential-nips-immunochemotherapy-for-peritoneal-metastasis-of-gastric-and-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05248581/trasplante-hepatico-de-donante-vivo-para-metastasis-hepaticas-irresecables-de-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05248581/living-donor-liver-transplant-for-unresectable-colorectal-liver-metastases 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05840263/intervencion-basada-en-la-atencion-plena-para-parejas-en-el-contexto-del-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05840263/couple-based-mindfulness-intervention-for-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04068610/columbia-1-nuevas-terapias-oncologicas-en-combinacion-con-quimioterapia-y-bevacizumab-como-terapia-de-primera-linea-en-el-crc-mss 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04068610/columbia-1-novel-oncology-therapies-in-combination-with-chemotherapy-and-bevacizumab-as-first-line-therapy-in-mss-crc 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06605430/cannabis-medicinal-en-pacientes-con-cancer-avanzado-de-pancreas-y-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06605430/medical-cannabis-in-patients-with-advanced-pancreatic-and-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06462963/oligocare-twics-ensayos-dentro-de-cohortes-ensayo-comparativo-de-la-toxicidad-aguda-en-la-radioterapia-estereotactica-ablativa-sbrt-en-una-sola-fraccion-frente-a-multiples-fracciones-para-el 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06462963/oligocare-twics-trials-within-cohorts-trial-comparing-acute-toxicity-in-single-fraction-vs-multiple-fraction-sbrt-for-metastasis-directed-treatment-sprint 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03908788/deteccion-de-la-aparicion-de-mutaciones-en-el-gen-ras-homologo-del-oncogen-viral-del-sarcoma-de-rata-en-el-adn-circulante-acido-desoxirribonucleico-en-pacientes-con-ccrc-metastasico-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03908788/detection-of-the-emergence-of-ras-rat-sarcoma-viral-oncogene-homolog-mutations-in-circulating-dna-deoxyribonucleic-acid-in-patients-with-mcrc-metastatic-colorectal-cancer-during-treatment-with-anti 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07263178/un-estudio-sobre-la-quimioterapia-paliativa-en-segunda-linea-y-posteriores-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07263178/a-study-of-second-and-later-line-palliative-chemotherapy-in-patients-with-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05068531/deteccion-temprana-del-fracaso-del-tratamiento-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05068531/early-detection-of-treatment-failure-in-metastatic-colorectal-cancer-patients 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05843188/estudio-de-hidroxicloroquina-con-folfiri-y-bevacizumab-en-cancer-colorrectal-metastasico-con-alto-nivel-de-dtp 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05843188/study-of-hydroxychloroquine-with-folfiri-and-bevacizumab-in-dtp-high-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04449874/un-estudio-para-evaluar-la-seguridad-la-farmacocinetica-y-la-actividad-de-gdc-6036-en-monoterapia-o-en-combinacion-en-participantes-con-tumores-solidos-avanzados-o-metastasicos-con-una-mutacion-kras 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04449874/a-study-to-evaluate-the-safety-pharmacokinetics-and-activity-of-gdc-6036-alone-or-in-combination-in-participants-with-advanced-or-metastatic-solid-tumors-with-a-kras-g12c-mutation 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07051785/fruquintinib-frente-a-bevacizumab-en-combinacion-con-irinotecan-liposomal-y-capecitabina-como-terapia-de-segunda-linea-para-el-cancer-colorrectal-metastasico-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07051785/fruquintinib-vs-bevacizumab-combined-with-irinotecan-liposome-and-capecitabine-as-second-line-therapy-for-advanced-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07283575/uso-de-la-metilacion-del-ctdna-para-monitorizar-el-tratamiento-del-cancer-colorrectal-metastasico-promet 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283575/using-ctdna-methylation-to-monitor-metastatic-colorectal-cancer-treatment-promet 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06115733/estudio-de-fuquinitinib-en-combinacion-con-capecitabina-como-tratamiento-de-mantenimiento-de-primera-linea-en-el-tratamiento-del-cancer-colorrectal-metastasico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06115733/study-of-fuquinitinib-combined-with-capecitabine-first-line-maintenance-in-the-treatment-of-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05727163/folfox-administrado-por-via-hai-mas-irinotecan-intravenoso-con-o-sin-bevacizumab-frente-a-folfoxiri-sistemico-con-o-sin-bevacizumab-en-pacientes-con-metastasis-hepaticas-colorrectales-crlm 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05727163/folfox-via-hai-plus-intravenous-irinotecan-with-or-without-bevacizumab-versus-systemic-folfoxiri-with-or-without-bevacizumab-in-initially-unresectable-ras-mutated-crlm-patients 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04680260/optimizacion-de-la-seleccion-del-tratamiento-y-el-seguimiento-en-el-cancer-colorrectal-oligo-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04680260/optimization-of-treatment-selection-and-follow-up-in-oligometastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04258137/adn-circulante-para-mejorar-el-pronostico-de-los-pacientes-oncologicos-un-estudio-aleatorizado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04258137/circulating-dna-to-improve-outcome-of-oncology-patient-a-randomized-study 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04245865/tocotrienol-y-bevacizumab-en-el-cancer-colorrectal-metastasico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04245865/tocotrienol-and-bevacizumab-in-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05815082/quimioterapia-adyuvante-guiada-por-ctdna-en-metastasis-hepaticas-del-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05815082/ctdna-guided-adjuvant-chemotherapy-in-liver-metastasis-of-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06053996/radioesterilizacion-hepatopulmonar-combinada-con-inmunoterapia 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06053996/hepatopulmonary-radio-sterilization-with-immunotherapy 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07290309/supervivientes-unidos-a-traves-de-ejercicios-guiados-a-distancia 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07290309/survivors-uniting-for-remote-guided-exercise 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07244705/un-estudio-de-abt-301-mas-tislelizumab-con-bevacizumab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-metastasico-pmmr-no-msi-h 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07244705/a-study-of-abt-301-plus-tislelizumab-with-bevacizumab-in-pmmr-non-msi-h-locally-advanced-or-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06679673/shr-1701-en-combinacion-con-shr2554-y-bp102-para-el-cmmr 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06679673/shr-1701-combined-with-shr2554-and-bp102-for-mcrc 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02246634/deteccion-de-metastasis-sincronicas-en-el-cancer-colorrectal-mediante-resonancia-magnetica-con-difusion-serenade 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT02246634/screening-for-synchronous-metastases-in-colorectal-cancer-with-dw-mri-serenade 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07050394/un-ensayo-de-expansion-de-dosis-de-hnf4-srrna-intravenoso-para-el-cancer-colorrectal-irresecable-o-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07050394/a-dose-expansion-trial-of-intravenous-hnf4-srrna-for-unresectable-or-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05705492/olanzapina-para-el-manejo-de-la-perdida-de-apetito-asociada-al-cancer-en-pacientes-con-cancer-avanzado-de-esofago-estomago-higado-pancreas-vias-biliares-colon-recto-o-pulmon 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05705492/olanzapine-for-the-management-of-cancer-associated-appetite-loss-in-patients-with-advanced-esophagogastric-hepatopancreaticobiliary-colorectal-or-lung-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07007689/un-estudio-multi-omico-del-cancer-colorrectal-con-mutacion-braf-v600e 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007689/a-multi-omics-study-of-braf-v600e-mutant-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07502014/un-estudio-clinico-de-iparomlimab-y-tuvonralimab-en-combinacion-con-fruquintinib-y-radioterapia-heterogenea-en-comparacion-con-fruquintinib-como-tratamiento-de-tercera-linea-y-en-lineas-posteriores 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07502014/a-clinical-study-of-iparomlimab-and-tuvonralimab-combined-with-fruquintinib-and-heterogeneous-radiotherapy-versus-fruquintinib-as-third-line-and-subsequent-line-treatment-for-metastatic-colorectal 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04771520/avapritinib-para-el-tratamiento-de-tumores-solidos-malignos-localmente-avanzados-o-metastasicos-con-mutacion-en-ckit-o-pdgfra 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04771520/avapritinib-for-the-treatment-of-ckit-or-pdgfra-mutation-positive-locally-advanced-or-metastatic-malignant-solid-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06513221/un-estudio-prospectivo-de-cancer-colorrectal-metastasico-de-tipo-mss-que-recibe-multiples-lineas-de-quimioterapia-estandar-bevacizumab-en-combinacion-con-adebrelimab 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06513221/a-prospective-study-of-mss-type-metastatic-colorectal-cancer-receiving-multiple-lines-of-standard-chemotherapy-bevacizumab-combined-with-adebrelimab 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06821048/estudio-de-la-terapia-car-t-dirigida-contra-el-cea-ptc13-en-el-tratamiento-de-tumores-solidos-malignos-avanzados-cea-positivos 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06821048/study-of-cea-targeting-car-t-ptc13-in-the-treatment-of-cea-positive-advanced-malignant-solid-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06681038/tratamiento-antitumoral-sistemico-con-o-sin-quimioterapia-en-aerosol-intraabdominal-a-presion-para-metastasis-peritoneales-de-cancer-de-colon-pipox02 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06681038/systemic-antitumor-treatment-with-or-without-pressurized-intraperitoneal-aerosol-chemotherapy-for-colon-peritoneal-metastases-pipox02 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07228832/estudio-de-fase-iii-con-ivonescimab-o-bevacizumab-en-combinacion-con-folfox-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07228832/phase-iii-study-of-ivonescimab-or-bevacizumab-combined-with-folfox-in-patients-with-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07007728/iparolimab-tuvonralimab-en-combinacion-con-bevacizumab-y-capeox-como-terapia-de-conversion-para-metastasis-hepaticas-del-cancer-colorrectal 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007728/iparomlimab-tuvonralimab-combined-with-bevacizumab-and-capeox-as-conversion-therapy-for-colorectal-cancer-liver-metastasis 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06283134/un-estudio-clinico-de-biottt001-en-combinacion-con-toripalimab-y-regorafenib-en-pacientes-con-cancer-colorrectal 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06283134/a-clinical-study-of-biottt001-in-combination-with-toripalimab-and-regorafenib-in-patients-with-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07309289/nalirifox-mas-terapia-dirigida-frente-a-folfox-mas-terapia-dirigida-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07309289/nalirifox-plus-targeted-therapy-versus-folfox-plus-targeted-therapy-as-first-line-treatment-for-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07221357/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-pumitamig-en-combinacion-con-quimioterapia-frente-a-bevacizumab-en-combinacion-con-quimioterapia-en-participantes-con-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07221357/a-study-to-evaluate-the-safety-and-efficacy-of-pumitamig-in-combination-with-chemotherapy-versus-bevacizumab-in-combination-with-chemotherapy-in-participants-with-previously-untreated-unresectable-or 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06959693/un-estudio-clinico-para-evaluar-la-eficacia-y-la-seguridad-de-envafolimab-en-combinacion-con-cetuximab-y-mfolfox6-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-mss-y-ras-braf-de-tipo-salvaje 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959693/a-clinical-study-to-evaluate-the-efficacy-and-safety-of-envafolimab-combined-with-cetuxima-and-mfolfox6-in-patients-with-mss-ras-braf-wild-type-metastatic-colorectal-cancer-mcrc 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06625775/estudio-abierto-con-bbo-10203-en-pacientes-con-tumores-solidos-avanzados 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06625775/open-label-study-of-bbo-10203-in-subjects-with-advanced-solid-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07504523/terapia-celular-t-personalizada-ineo-vac-t01-en-cancer-colorrectal-avanzado 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07504523/personalized-t-cell-therapy-ineo-vac-t01-in-advanced-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05787197/ctdna-en-pacientes-con-crc-sometidos-a-cirugia-con-intencion-curativa-para-metastasis-hepaticas 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05787197/ctdna-in-crc-patients-undergoing-curative-intent-surgery-for-liver-metastases 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06135571/estudio-sobre-los-patrones-de-metastasis-en-el-ganglio-linfatico-numero-253-en-el-cancer-de-colon-y-recto-izquierdo 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06135571/study-on-the-no-253-lymph-node-metastasis-patterns-in-left-sided-colon-and-rectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04678583/reseccion-anatomica-de-metastasis-hepaticas-en-pacientes-con-cancer-colorrectal-con-mutaciones-en-los-genes-ras 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04678583/anatomical-resection-of-liver-metastases-in-patients-with-ras-mutated-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202183/ejercicio-fisico-y-microbiota-intestinal-en-pacientes-con-cancer-colorrectal-de-inicio-temprano-que-reciben-quimioterapia-el-ensayo-courage 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202183/exercise-for-gut-microbiome-in-patients-with-young-onset-colorectal-cancer-undergoing-chemotherapy-the-courage-trial 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04798898/mejora-de-la-supervivencia-en-metastasis-hepaticas-de-cancer-colorrectal-mediante-la-inmunostimulacion-inducida-por-ablacion-por-radiofrecuencia 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04798898/improving-survival-of-colorectal-liver-metastases-by-rfa-mediated-immunostimulation 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07509398/fmt-en-combinacion-con-la-terapia-estandar-de-primera-linea-en-el-cancer-colorrectal-inicialmente-irresecable 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509398/fmt-combined-with-standard-first-line-therapy-in-initially-unresectable-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06111105/guia-mrd-01-crc-validacion-clinica-y-evaluacion-comparativa-de-los-mejores-diagnosticos-de-ctadn-en-el-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06111105/guide-mrd-01-crc-clinical-validation-and-benchmarking-of-top-performing-ctdna-diagnostics-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07510932/fruquintinib-en-pacientes-con-cancer-colorrectal-metastasico-refractario-a-las-quimioterapias-estandar-en-corea-del-sur-first-k 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07510932/fruquintinib-in-patients-with-metastatic-colorectal-cancer-refractory-to-standard-chemotherapies-in-south-korea-patients-first-k 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622550/un-estudio-clinico-multicentrico-de-un-solo-brazo-que-evalua-la-combinacion-de-fruquintinib-con-serplulimab-y-quimioterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622550/a-single-arm-multicenter-clinical-study-of-fruquintinib-combined-with-serplulimab-and-chemotherapy-as-first-line-treatment-for-patients-with-ras-braf-mutated-advanced-colorectal-cance 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05299840/impacto-del-uso-del-dispositivo-oncogramme-r-en-la-seleccion-del-tratamiento-de-primera-linea-para-pacientes-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05299840/impact-of-using-the-oncogramme-r-device-to-select-the-first-line-of-treatment-for-patients-with-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05854498/irinotecan-liposomal-en-combinacion-con-tas102-y-bevacizumab-para-pacientes-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05854498/liposomal-irinotecan-with-tas102-and-bevacizumab-for-patients-with-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07623174/un-estudio-de-fruquintinib-en-adultos-con-cancer-colorrectal-metastasico-en-polonia 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07623174/a-study-of-fruquintinib-in-adults-with-metastatic-colorectal-cancer-in-poland 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06470178/un-estudio-en-el-mundo-real-sobre-la-terapia-neoadyuvante-de-conversion-para-el-cancer-colorrectal-con-quimioterapia-y-agentes-dirigidos-antiangiogenicos 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06470178/a-real-world-study-of-neoadjuvant-conversion-therapy-for-colorectal-cancer-with-chemotherapy-and-anti-angiogenic-targeted-agents 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06282445/eficacia-y-seguridad-de-la-quimioterapia-con-xelox-oxaliplatino-capecitabina-y-bevacizumab-en-combinacion-con-adebrelimab-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06282445/efficacy-and-safety-of-chemotherapy-with-xelox-oxaliplatin-capecitabine-and-bevacizumab-in-combination-with-adebrelimab-in-first-line-treatment-of-microsatellite-stable-mss-initially-unresectable 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07321847/inyeccion-de-ip-001-en-tumores-hepaticos-sometidos-a-ablacion-termica-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07321847/injection-of-ip-001-into-thermally-ablated-hepatic-tumors-in-patients-with-colorectal-liver-metastases 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05931445/estudio-de-resultados-informados-por-el-paciente-mediante-un-sistema-de-monitorizacion-electronica-para-cancer-solido-avanzado-o-metastasico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05931445/patient-reported-outcomes-study-using-electronic-monitoring-system-for-advanced-or-metastatic-solid-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07328087/colonyvaq-tm-una-vacuna-neoantigenica-personalizada-guiada-por-metodos-cuanticos-y-clasicos-para-el-cancer-colorrectal-en-estadio-iii-con-mss 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07328087/colonyvaq-tm-a-quantum-classical-guided-personalized-neoantigen-vaccine-for-mss-stage-iii-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06699836/ensayo-de-fase-ii-clover-que-evalua-el-uso-de-leronlimab-un-farmaco-dirigido-al-ccr5-en-combinacion-con-quimioterapia-oral-y-un-regimen-enriquecido-con-un-inhibidor-del-vegf 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06699836/the-phase-2-ccr5-targeting-leronlimab-with-oral-chemotherapy-and-vegf-inhibitor-enriched-regimen-trial-clover 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06787105/fruquintinib-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06787105/fruquintinib-in-patients-with-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03303495/un-estudio-comparativo-de-folfiri-en-segunda-linea-bevacizumab-frente-a-irinotecan-bevacizumab-en-pacientes-con-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03303495/a-study-of-2nd-line-folfiri-bevacizumab-vs-irinotecan-bevacizumab-in-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07525206/un-estudio-para-evaluar-el-uso-de-telisotuzumab-adizutecan-intravenoso-iv-en-combinacion-con-bevacizumab-iv-en-comparacion-con-el-tratamiento-estandar-con-bevacizumab-iv-en-combinacion-con 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07525206/a-study-to-access-intravenous-iv-telisotuzumab-adizutecan-in-combination-with-iv-bevacizumab-compared-to-standard-of-care-iv-bevacizumabin-combination-with-oral-trifluridine-and-tipiracil-in-adult 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05746897/un-estudio-de-fase-i-abierto-multicentrico-y-de-primera-administracion-en-humanos-de-nm1f-anti-pvrig-en-pacientes-con-tumores-solidos-avanzados 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05746897/a-first-in-human-phase-i-open-label-multicenter-study-of-nm1f-anti-pvrig-in-patients-with-advanced-solid-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05131919/pembrolizumab-para-el-tratamiento-de-cancer-colorrectal-localmente-avanzado-irresecable-y-no-metastasico-con-dmmr 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05131919/pembrolizumab-for-locally-advanced-irresectable-non-metastatic-dmmr-colorectal-cancers 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06126419/aplicacion-de-la-terapia-con-insulina-en-dosis-altas-para-mejorar-la-funcion-y-regeneracion-hepatica 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06126419/application-of-high-dose-insulin-therapy-to-improve-liver-function-and-regeneration 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06395519/un-estudio-del-inhibidor-de-parg-etx-19477-en-pacientes-con-tumores-solidos-avanzados 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06395519/a-study-of-parg-inhibitor-etx-19477-in-patients-with-advanced-solid-malignancies 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07333651/implante-de-semillas-de-125i-mas-terapia-sistemica-para-el-cancer-de-pulmon-de-celulas-no-pequenas-cpcnp-u-el-cancer-colorrectal-oligoprogresivo 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07333651/125i-seed-implantation-plus-systemic-therapy-for-oligoprogressive-nsclc-or-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06663319/un-estudio-de-jnj-89402638-para-cancer-colorrectal-y-gastrico-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06663319/a-study-of-jnj-89402638-for-metastatic-colorectal-and-gastric-cancers 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07337551/acetato-de-gossipol-folfiri-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-mutacion-en-tp53-y-expresion-positiva-de-lrpprc 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07337551/gossypol-acetate-folfiri-bev-in-mcrc-with-tp53-mutant-and-lrpprc-positive 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05704985/evaluacion-de-la-seguridad-y-los-biomarcadores-mediante-el-uso-de-dk210-egfr-en-tumores-localmente-avanzados-o-metastasicos-egfr 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05704985/evaluating-safety-and-biomarkers-using-dk210-egfr-for-locally-advanced-or-metastatic-egfr-tumors 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06543836/tratamiento-guiado-por-ctdna-con-tki-mas-inhibidor-de-pd-1-en-el-cancer-colorrectal-avanzado-pmmr-mss 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06543836/ctdna-guided-treatment-of-tki-plus-pd-1-inhibitor-for-advanced-pmmr-mss-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT02804815/add-aspirin-un-ensayo-clinico-que-evalua-los-efectos-de-la-aspirina-sobre-la-recurrencia-de-la-enfermedad-y-la-supervivencia-tras-la-terapia-primaria-en-tumores-solidos-no-metastasicos-comunes 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02804815/add-aspirin-a-trial-assessing-the-effects-of-aspirin-on-disease-recurrence-and-survival-after-primary-therapy-in-common-non-metastatic-solid-tumours 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06440902/exploracion-de-estrategias-terapeuticas-para-el-cancer-colorrectal-metastasico-con-mutacion-nras-de-tipo-salvaje-basada-en-el-adn-tumoral-circulante 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440902/exploration-of-therapeutic-strategies-for-neoras-wild-type-metastatic-colorectal-cancer-based-on-circulating-tumor-dna 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04673955/investigacion-en-la-practica-clinica-del-inhibidor-de-braf-encorafenib-y-el-cetuximab-como-tratamiento-de-nueva-generacion-para-el-ccrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04673955/braf-inhibitor-encorafenib-and-cetuximab-real-life-investigation-of-next-generation-crc-treatment 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05755672/biomarcadores-durante-el-tratamiento-en-el-cancer-colorrectal-metastasico-para-mejorar-la-calidad-de-vida 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05755672/on-treatment-biomarkers-in-metastatic-colorectal-cancer-for-life 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05382442/un-estudio-de-ak112-con-o-sin-ak117-en-el-cancer-colorrectal-metastasico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05382442/a-study-of-ak112-with-or-without-ak117-in-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05677113/un-estudio-de-qbeco-frente-a-placebo-en-el-tratamiento-del-cancer-colorrectal-que-se-ha-extendido-al-higado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05677113/a-study-of-qbeco-versus-placebo-in-the-treatment-of-colorectal-cancer-that-has-spread-to-the-liver 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134205/estudio-de-jmt101-en-combinacion-con-irinotecan-como-tratamiento-en-3a-linea-en-el-cancer-colorrectal-metastasico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134205/the-study-of-jmt101-combined-with-irinotecan-as-a-3rd-line-treatment-in-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06353854/cohorte-nacional-prospectiva-para-evaluar-biomarcadores-predictivos-de-resistencia-a-la-inmunoterapia-en-pacientes-con-cancer-colorrectal-metastasico-msi-dmmr-coresim 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06353854/prospective-national-cohort-evaluating-predictive-biomarkers-of-resistance-to-immunotherapy-in-patients-with-msi-dmmr-metastatic-colorectal-cancer-coresim 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06820463/un-estudio-para-evaluar-los-eventos-adversos-y-la-eficacia-de-la-administracion-intravenosa-iv-de-telisotuzumab-adizutecan-en-combinacion-con-oxaliplatino-iv-fluorouracilo-acido-folinico-leucovorina 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06820463/a-study-to-evaluate-the-adverse-events-and-efficacy-of-intravenous-iv-of-telisotuzumab-adizutecan-in-combination-with-iv-oxaliplatin-fluorouracil-folinic-acid-leucovorin-bevacizumab-panitumumab-in 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07128355/botensilimab-balstilimab-y-radioterapia-estereotactica-ablativa-sbrt-en-el-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07128355/botensilimab-balstilimab-and-sbrt-in-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05629442/ctdna-y-preservacion-de-organos-respuesta-completa-patologica-en-el-cancer-de-recto 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05629442/ctdna-and-organ-preservation-pathologic-cr-in-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07271355/quimioterapia-intraabdominal-en-aerosol-a-presion-con-mitomicina-para-el-tratamiento-del-cancer-de-apendice-o-de-colon-recto-irresecable-con-metastasis-peritoneales-el-ensayo-impact 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07271355/pressurized-intraperitoneal-aerosolized-chemotherapy-with-mitomycin-for-the-treatment-of-unresectable-appendix-or-colorectal-cancer-with-peritoneal-metastases-the-impact-trial 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06149481/estudio-de-fase-i-ii-del-regimen-de-inmunoterapia-combinada-sx-682-vacuna-triadeno-retifanlimab-y-agonista-de-il-15-n-803-star15-para-el-cancer-colorrectal-metastasico-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06149481/phase-i-ii-study-of-the-combination-immunotherapy-regimen-sx-682-triadeno-vaccine-retifanlimab-and-il-15-agonist-n-803-star15-for-metastatic-colorectal-cancer-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06607458/evaluacion-de-la-seguridad-y-la-eficacia-del-tratamiento-con-melfalan-a-dosis-altas-administrado-directamente-en-el-higado-seguido-de-tratamiento-con-un-farmaco-oncologico-aprobado-o-con-el-farmaco 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06607458/evaluation-of-the-safety-and-efficacy-of-treatment-w-high-dose-melphalan-given-directly-into-the-liver-followed-by-treatment-w-approved-cancer-treatment-or-approved-cancer-treatment-alone-in-patients 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05747716/terapia-de-radiacion-estereotactica-sbrt-combinada-con-fruquintinib-mas-un-anticuerpo-anti-pd-1-ctla-4-como-tratamiento-de-tercera-linea-en-pacientes-con-mcrc 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05747716/sbrt-combined-with-fruquintinib-plus-pd-1-ctla-4-antibody-for-third-line-treatment-in-mcrc 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06227728/analisis-de-la-dinamica-de-pd-l1-tmb-msi-y-ctdna-para-predecir-y-monitorizar-la-respuesta-a-la-inmunoterapia-en-el-cancer-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06227728/analysis-of-pd-l1-tmb-msi-and-ctdna-dynamics-to-predict-and-monitor-response-to-immunotherapy-in-metastatic-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03449914/el-estudio-gold-g8-en-pacientes-de-edad-avanzada 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03449914/the-gold-study-g8-in-older-patients 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05310643/nivolumab-e-ipilimumab-en-pacientes-con-mcrc-dmmr-msi-refractarios-a-anti-pd1 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05310643/nivolumab-and-ipilimumab-in-anti-pd1-resistant-dmmr-msi-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07552207/comparacion-de-la-pet-rm-con-68ga-ga-ctr-fapi-y-18f-fdg-para-la-estadificacion-de-los-ganglios-linfaticos-en-el-cancer-de-recto 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07552207/comparison-of-68ga-ga-ctr-fapi-and-18f-fdg-pet-mri-for-lymph-node-staging-in-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07359456/evaluacion-de-ivonescimab-en-combinacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal-metastasico-sin-metastasis-hepaticas 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07359456/testing-ivonescimab-in-combination-with-chemotherapy-in-patients-with-metastatic-colorectal-cancers-without-liver-metastases 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06411600/terapia-combinada-para-el-crcm-metastasico-con-mutacion-braf-v600e 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06411600/combination-therapy-for-braf-v600e-metastatic-crcm 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07025239/ql1706-en-inyeccion-combinado-con-bevacizumab-y-xelox-frente-a-placebo-combinado-con-bevacizumab-y-xelox-como-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-irresecable 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07025239/ql1706-injection-plus-bevacizumab-and-xelox-vs-placebo-plus-bevacizumab-and-xelox-as-first-line-treatment-of-unresectable-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06434090/irinotecan-liposomal-mas-bevacizumab-en-el-cancer-colorrectal-metastasico-refractario-a-irinotecan 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06434090/liposomal-irinotecan-plus-bevacizumab-in-irinotecan-refractory-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06922383/un-estudio-clinico-de-arfolitixorina-en-pacientes-con-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06922383/a-clinical-study-of-arfolitixorin-in-patients-with-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05759728/un-estudio-de-cna3103-celulas-car-t-autologas-dirigidas-a-lgr5-administrado-a-sujetos-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05759728/a-study-of-cna3103-lgr5-targeted-autologous-car-t-cells-administered-to-subjects-with-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07364656/analisis-de-la-presencia-y-los-efectos-sobre-la-funcion-cardiaca-de-los-autoanticuerpos-anti-nav1-5-en-pacientes-con-tumores-metastasicos 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07364656/analysis-of-the-presence-and-cardiac-functional-effects-of-anti-nav1-5-autoantibodies-in-patients-with-metastatic-tumors 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05985954/estudio-de-fase-1b-abierto-con-ulixertinib-y-cetuximab-o-ulixertinib-en-combinacion-con-cetuximab-y-encorafenib-en-pacientes-con-cancer-colorrectal-irresecable-o-metastasico-que-previamente-han 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985954/open-label-phase-1b-study-of-ulixertinib-and-cetuximab-or-ulixertinib-in-combination-with-cetuximab-and-encorafenib-in-patients-with-unresectable-or-metastatic-colorectal-cancer-who-have-previously 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07565831/estudio-sobre-la-prediccion-de-metastasis-en-los-ganglios-linfaticos-regionales-en-el-cancer-colorrectal-mediante-tomografia-computarizada-espectral-combinada-con-msi 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07565831/study-on-the-prediction-of-regional-lymph-node-metastasis-in-colorectal-cancer-by-spectral-ct-combined-with-msi 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05639413/una-cohorte-prospectiva-clinico-biologica-de-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-brafv600e 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05639413/a-clinical-biological-prospective-cohort-of-patients-with-brafv600e-mutated-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06858969/chidamida-en-combinacion-con-un-inhibidor-de-pd-1-bevacizumab-y-xelox-para-el-cancer-colorrectal-metastasico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06858969/chidamide-in-combination-with-pd-1-inhibitor-bevacizumab-and-xelox-for-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05556473/pet-ct-con-f-triptofano-en-canceres-humanos 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05556473/f-tryptophan-pet-ct-in-human-cancers 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06940921/sbrt-ldrt-cadonilimab-para-el-cancer-gastrico-colorrectal-y-ovarico-avanzado-con-metastasis-peritoneales 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940921/sbrt-ldrt-cadonilimab-for-advanced-gastric-colorectal-and-ovarian-cancers-with-peritoneal-metastases 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06268015/optimizacion-de-botensilimab-y-balstilimab-en-el-cancer-colorrectal 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06268015/botensilimab-and-balstilimab-optimization-in-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224815/biomarcadores-de-cfdna-5mc-5hmc-para-predecir-la-respuesta-a-la-quimioterapia-en-el-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224815/cfdna-5mc-5hmc-biomarkers-to-predict-chemotherapy-response-in-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06808685/estudio-nacional-multicentrico-en-el-mundo-real-para-evaluar-la-eficacia-y-la-seguridad-del-bevacizumab-biosimilar-elovie 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06808685/real-world-multicenter-national-study-to-evaluate-the-effectiveness-and-safety-of-biosimilar-bevacizumab-elovie 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06848465/terapia-de-radiacion-intrahepatica-guiada-por-imagenes-combinada-con-inmunoterapia-y-quimioterapia-para-el-cancer-colorrectal-con-metastasis-hepaticas 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06848465/ldrt-combined-with-immunochemotherapy-for-colorectal-cancer-with-liver-metastasis 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05314400/gadoxetato-resonancia-magnetica-abreviada-en-el-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05314400/gadoxetate-abbreviated-mri-in-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05489211/estudio-de-dato-dxd-como-monoterapia-y-en-combinacion-con-agentes-antineoplasicos-en-pacientes-con-tumores-solidos-avanzados-tropion-pantumor03 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05489211/study-of-dato-dxd-as-monotherapy-and-in-combination-with-anti-cancer-agents-in-patients-with-advanced-solid-tumours-tropion-pantumor03 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07385521/el-uso-de-la-inteligencia-artificial-para-la-prediccion-de-la-recurrencia-tras-la-reseccion-de-metastasis-hepaticas-de-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07385521/the-use-of-artificial-intelligence-for-the-prediction-of-recurrence-after-resection-of-colorectal-liver-metastases 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07149623/distribucion-de-los-ganglios-linfaticos-metastasicos-en-el-mesenterio-ileal-en-el-cancer-de-ciego-y-del-colon-ascendente-proximal 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07149623/metastatic-lymph-node-distribution-in-the-ileum-mesentery-of-cecal-and-proximal-ascending-colon-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03488953/trasplante-de-higado-con-donante-vivo-y-hepatectomia-en-dos-etapas-para-pacientes-con-metastasis-hepaticas-irresecables-aisladas-de-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03488953/living-donor-liver-transplantation-with-two-stage-hepatectomy-for-patients-with-isolated-irresectable-colorectal-liver-metastases 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06528353/deteccion-mediante-biomarcadores-sanguineos-en-el-cribado-de-cpc-impulsado-por-el-vph 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06528353/blood-biomarkers-based-screening-for-hpv-driven-opc 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06008054/un-estudio-de-si-b003-bl-b01d1-si-b003-y-bl-b01d1-anticuerpo-monoclonal-anti-pd-1-en-pacientes-con-cancer-de-esofago-localmente-avanzado-o-metastasico-cancer-gastrico-cancer-colorrectal-y-otros 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008054/a-study-of-si-b003-bl-b01d1-si-b003-and-bl-b01d1-pd-1-monoclonal-antibody-in-patients-with-locally-advanced-or-metastatic-esophageal-cancer-gastric-cancer-colorectal-cancer-and-other-gastrointestinal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07395063/un-estudio-clinico-sobre-el-tratamiento-del-cancer-colorrectal-metastasico-en-segunda-linea-o-posterior 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07395063/a-clinical-study-on-the-treatment-of-metastatic-colorectal-cancer-at-the-second-line-or-beyond 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940778/biopsia-liquida-centrada-en-las-celulas-tumorales-circulantes-y-el-adn-tumoral-circulante-como-herramienta-de-medicina-de-precision-en-los-tumores-gastrointestinales 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940778/liquid-biopsy-focusing-on-circulating-tumor-cells-and-circulating-tumor-dna-as-precision-medicine-in-gastrointestinal-tumors 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07399236/prediccion-basada-en-inteligencia-artificial-de-la-metastasis-hepatica-en-el-cancer-colorrectal-un-estudio-retrospectivo 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07399236/ai-based-prediction-of-liver-metastasis-in-colorectal-cancer-a-retrospective-study 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079462/comparacion-de-la-radioterapia-abdominal-guiada-por-pet-con-68ga-fapi-combinada-con-la-terapia-estandar-de-segunda-linea-y-cadonilimab-frente-a-la-terapia-estandar-de-segunda-linea-en-el-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079462/comparing-18f-fapi-pet-guided-abdominal-radiotherapy-combined-with-second-line-standard-therapy-and-cadonilimab-versus-second-line-standard-therapy-in-colorectal-cancer-with-peritoneal-metastasis 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06999252/rimegepant-en-combinacion-con-un-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-con-metastasis-hepaticas 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06999252/rimegepant-combined-with-pd-1-in-liver-metastasis-colorectal-cancer-patients 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07409805/vacuna-ymn-136-para-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-que-presentan-progresion-tras-el-tratamiento-en-tercera-linea 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07409805/ymn-136-vaccine-for-patients-with-liver-metastasis-of-colorectal-cancer-progressing-after-third-line-treatment 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05195710/radioembolizacion-preoperatoria-con-y-90-para-el-control-tumoral-y-la-hipertrofia-del-futuro-remanente-hepatico-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05195710/preoperative-y-90-radioembolization-for-tumor-control-and-future-liver-remnant-hypertrophy-in-patients-with-colorectal-liver-metastases 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07133750/pm8002-bnt327-en-combinacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07133750/pm8002-bnt327-in-combination-with-chemotherapy-in-patients-with-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05985109/kn-046-regorafenib-mas-otro-tratamiento-en-cancer-colorrectal-metastasico-mss 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985109/kn-046-plus-regorafenib-in-mss-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07054047/mejorando-el-diagnostico-y-el-tratamiento-de-los-pacientes-con-cancer-de-recto 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07054047/improving-diagnosis-and-treatment-for-patients-with-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06634875/isunakinra-en-monoterapia-y-en-combinacion-con-pembrolizumab-en-pacientes-con-cancer-colorrectal-mss 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06634875/isunakinra-alone-and-in-combination-with-pembrolizumab-in-patients-with-colorectal-cancer-mss 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07193862/estudio-piloto-de-un-microdispositivo-implantable-para-la-evaluacion-in-situ-de-la-respuesta-a-farmacos-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07193862/pilot-study-of-an-implantable-microdevice-for-in-situ-evaluation-of-drug-response-in-patients-with-colorectal-liver-metastasis 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07653685/un-estudio-clinico-de-tqb2930-inyectable-y-quimioterapia-con-o-sin-bevacizumab-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07653685/a-clinical-study-of-tqb2930-injection-and-chemotherapy-with-or-without-bevacizumab-in-the-treatment-of-advanced-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02980510/comparacion-de-folfirinox-con-panitumumab-frente-a-mfolfox6-con-panitumumab-en-pacientes-con-cancer-colorrectal-metastasico-con-ras-b-raf-de-tipo-salvaje 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02980510/comparison-folfirinox-panitumumab-vs-mfolfox6-panitumumab-in-ras-b-raf-wild-type-metastatic-colorectal-cancer-patients 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06218810/cadonilimab-en-combinacion-con-bevacizumab-y-el-regimen-folfox-para-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-avanzado-irresecable-y-de-tipo-mss-con-mutacion-en-los-genes-ras 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06218810/cadonilimab-in-combination-with-bevacizumab-and-folfox-regimen-for-the-first-line-treatment-of-advanced-unresectable-mss-type-ras-mutated-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT01531595/estudio-de-bevacizumab-en-combinacion-con-esquemas-alternos-de-xeliri-y-xelox-en-cancer-colorrectal-metastasico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT01531595/study-of-bevacizumab-in-combination-with-alternating-xeliri-and-xelox-in-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04516681/combinacion-de-acido-ascorbico-intravenoso-y-adebrelimab-en-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04516681/combination-of-iv-ascorbic-acid-and-adebrelimab-in-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07656038/nelmastobart-en-combinacion-con-tas-102-y-bevacizumab-en-el-cancer-colorrectal-recurrente-metastasico 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07656038/nelmastobart-in-combination-with-tas-102-and-bevacizumab-in-recurrent-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04776655/estudio-en-pacientes-con-mcrc-cancer-colorrectal-metastasico-que-compara-el-analisis-de-tejidos-ras-braf-salvajes-y-biopsias-liquidas-ras-mutadas-y-evalua-el-tratamiento-con-folfiri-mas-cetuximab-o 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04776655/study-in-mcrc-patients-ras-braf-wt-tissue-and-ras-mutated-liquid-biopsy-to-compare-folfiri-plus-cetuximab-or-bevacizumab 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05296681/producto-microbiano-para-promover-la-salud-del-microbioma-y-mejorar-la-administracion-de-la-quimioterapia 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05296681/microbiotic-product-to-promote-microbiome-health-and-improve-chemotherapy-delivery 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05963490/regorafenib-solo-o-en-combinacion-con-radioterapia-hipofraccionada-de-baja-dosis-mas-toripalimab-para-el-cancer-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05963490/regorafenib-alone-or-in-combination-with-hypofractionated-low-dose-radiotherapy-plus-toripalimab-for-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06024837/rendimiento-de-la-tomografia-computarizada-espectral-en-pacientes-con-cancer-colorrectal-metastasico-un-estudio-multicentrico-prospectivo 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06024837/performance-of-spectral-ct-scan-in-patients-with-metastatic-colorectal-cancer-a-prospective-multicentre-study 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04579380/estudio-basket-con-tucatinib-y-trastuzumab-en-tumores-solidos-con-alteraciones-de-her2 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04579380/basket-study-of-tucatinib-and-trastuzumab-in-solid-tumors-with-her2-alterations 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04585750/evaluacion-de-pc14586-en-pacientes-con-tumores-solidos-avanzados-que-presentan-una-mutacion-y220c-en-el-gen-tp53-pynnacle 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04585750/the-evaluation-of-pc14586-in-patients-with-advanced-solid-tumors-harboring-a-tp53-y220c-mutation-pynnacle 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04938986/interes-del-immunoscore-r-como-herramienta-complementaria-postoperatoria-para-la-deteccion-del-riesgo-de-recurrencia-en-pacientes-con-cancer-colorrectal-no-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04938986/interest-of-the-immunoscore-r-as-a-post-operative-complementary-tool-for-the-detection-of-the-risk-of-recurrence-in-patients-with-nonmetastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05768503/comparacion-de-chidamide-sintilimab-bevacizumab-con-el-regimen-estandar-de-segunda-linea-folfiri-bevacizumab-en-pacientes-con-mcrc-avanzado-mss-pmmr 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05768503/comparing-chidamide-sintilimab-bev-with-standard-second-line-folfiri-bev-in-advanced-mss-pmmr-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06630624/determinacion-de-la-dosis-eficacia-y-respuesta-inmunologica-de-ip-001-tras-ablacion-por-microondas-mwa-o-ablacion-por-radiofrecuencia-irreversible-ire-en-pacientes-con-metastasis-hepaticas-de-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06630624/dose-finding-efficacy-and-immunological-response-of-ip-001-following-mwa-or-ire-for-crlm 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05229003/irinotecan-mas-anlotinib-o-ademas-en-combinacion-con-penpulimab-para-el-tratamiento-de-segunda-linea-del-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05229003/irinotecan-plus-anlotinib-or-further-in-combination-with-penpulimab-for-second-line-treatment-of-mcrc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06446557/desescalada-o-cambio-de-tratamiento-segun-la-variacion-del-adn-tumoral-circulante-tras-2-ciclos-de-quimioterapia-combinada-mas-terapia-dirigida-en-el-cancer-colorrectal-metastasico-irresecable 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06446557/de-scalation-or-switch-of-treatment-according-to-circulating-tumor-dna-variation-after-2-cycles-of-doublet-chemotherapy-plus-targeted-agent-in-metastatic-unresectable-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04929223/un-estudio-que-evalua-la-seguridad-y-la-eficacia-de-las-terapias-dirigidas-en-subpoblaciones-de-pacientes-con-cancer-colorrectal-metastasico-intrinsic 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04929223/a-study-evaluating-the-safety-and-efficacy-of-targeted-therapies-in-subpopulations-of-patients-with-metastatic-colorectal-cancer-intrinsic 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03965234/perfusion-pulmonar-para-el-control-de-la-enfermedad-residual-minima-en-pacientes-con-sarcoma-o-metastasis-de-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03965234/pulmonary-suffusion-in-controlling-minimal-residual-disease-in-patients-with-sarcoma-or-colorectal-metastases 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008119/eficacia-y-seguridad-de-tunlametinib-mas-vemurafenib-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-braf-v600e 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008119/efficacy-and-safety-of-tunlametinib-plus-vemurafenib-in-patients-with-braf-v600e-mutant-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT01479608/trasplante-hepatico-y-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT01479608/liver-transplantation-and-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446387/un-estudio-clinico-de-iparomlimab-y-tuvonralimab-en-combinacion-con-bevacizumab-y-un-regimen-de-capox-mcapiri-alternado-cada-tres-semanas-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446387/a-clinical-study-of-iparomlimab-and-tuvonralimab-combined-with-bevacizumab-and-alternating-triweekly-capox-mcapiri-regimen-as-first-line-treatment-for-unresectable-advanced-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446465/quimioterapia-folfox-combinada-con-fruquintinib-y-serplulimab-como-terapia-de-conversion-de-primera-linea-para-cancer-colorrectal-pmmr-mss-inicialmente-irresecable 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446465/folfox-chemotherapy-combined-with-fruquintinib-and-serplulimab-as-first-line-conversion-therapy-for-initially-unresectable-pmmr-mss-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04616495/trasplante-hepatico-en-pacientes-con-metastasis-hepaticas-irresecables-de-cancer-colorrectal 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04616495/liver-transplantation-in-patients-with-unresectable-colorectal-liver-metastases 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06979908/un-estudio-clinico-sobre-la-eficacia-y-la-seguridad-de-fruquintinib-en-combinacion-con-un-anticuerpo-monoclonal-anti-pd-1-y-chidamide-en-el-cancer-colorrectal-metastasico-refractario-mss 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06979908/a-clinical-study-on-the-efficacy-and-safety-of-fruquintinib-in-combination-with-pd-1-monoclonal-antibody-and-chidamide-in-refractory-mss-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783569/un-estudio-de-escalada-y-expansion-en-humanos-el-primero-de-su-tipo-en-pacientes-con-tumores-solidos-avanzados 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783569/a-first-in-human-escalation-and-expansion-study-of-patients-with-advanced-solid-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06500052/un-estudio-de-bl-m17d1-en-pacientes-con-cancer-gastrointestinal-her2-positivo-de-baja-expresion-localmente-avanzado-o-metastasico-y-otros-tumores-solidos 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06500052/a-study-of-bl-m17d1-in-patients-with-locally-advanced-or-metastatic-her2-positive-lower-expression-gastrointestinal-cancer-and-other-solid-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04008030/un-estudio-de-nivolumab-nivolumab-mas-ipilimumab-o-quimioterapia-a-eleccion-del-investigador-para-el-tratamiento-de-participantes-con-cancer-colorrectal-metastasico-mcrc-con-deficiencia-en-la 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04008030/a-study-of-nivolumab-nivolumab-plus-ipilimumab-or-investigator-s-choice-chemotherapy-for-the-treatment-of-participants-with-deficient-mismatch-repair-dmmr-microsatellite-instability-high-msi-h 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07202364/un-estudio-de-yl202-en-pacientes-con-tumores-solidos-avanzados 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07202364/a-study-of-yl202-in-patients-with-advanced-solid-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06509126/panitumumab-administrado-de-forma-intermitente-o-continua-en-combinacion-con-folfiri-para-el-cancer-colorrectal-metastasico-de-lado-izquierdo-con-mutaciones-ras-b-raf-de-tipo-salvaje 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06509126/intermittent-or-continuous-panitumumab-plus-folfiri-for-left-sided-ras-b-raf-wild-type-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079631/un-estudio-clinico-para-evaluar-si-un-tratamiento-experimental-denominado-bnt314-utilizado-en-combinacion-con-otro-tratamiento-experimental-bnt327-y-quimioterapia-es-beneficioso-y-seguro-para 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079631/a-clinical-study-to-test-if-an-investigational-treatment-called-bnt314-when-used-in-combination-with-another-investigational-treatment-bnt327-and-chemotherapy-is-beneficial-and-safe-for-patients-with 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06079242/estudio-observacional-sobre-la-terapia-con-sir-spheres-para-el-tratamiento-de-tumores-hepaticos-metastasicos-irresecables-procedentes-de-cancer-colorrectal-primario 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06079242/observational-study-for-sir-spheres-therapy-for-the-treatment-of-unresectable-metastatic-liver-tumors-from-primary-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06856837/ikf-aio-quintis-evaluacion-de-fruquintinib-en-combinacion-con-tislelizumab-en-cancer-colorrectal-metastasico-con-microsatelites-estables-reparacion-deficiente-de-errores-de-apareamiento-mss-pmmr-sin 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856837/ikf-aio-quintis-evaluating-fruquintinib-in-combination-with-tislelizumab-in-microsatellite-stable-proficient-mismatch-repair-mss-pmmr-metastatic-colorectal-cancer-without-active-liver-metastases 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06929013/cinetica-de-eliminacion-del-nucleosoma-y-ctcf-en-sangre-en-el-cancer-colorrectal-con-metastasis-peritoneales 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06929013/blood-clearance-kinetics-of-the-nucleosome-and-ctcf-in-peritoneal-metastasis-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07457541/imagenes-moleculares-de-la-expresion-de-la-proteina-de-activacion-de-fibroblastos-mediante-el-uso-de-fapi-marcado-con-tecnecio-99m-hynic 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07457541/molecular-imaging-of-fibroblast-activation-protein-expression-using-labeled-technetium-99m-hynic-fapi 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06563986/ftd-tpi-bevacizumab-y-radioembolizacion-con-microsferas-de-166ho-en-el-cancer-colorrectal-metastasico-refractario 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563986/ftd-tpi-bevacizumab-and-radioembolization-with-166ho-microspheres-in-refractory-metastatic-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06788171/pulsar-en-combinacion-con-un-anticuerpo-anti-pd-1-y-quimioterapia-mas-bevacizumab-para-el-tratamiento-del-cancer-colorrectal-metastasico-ccrm 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06788171/pulsar-combined-with-pd-1-ab-and-chemotherapy-plus-bev-for-crlm 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07213570/stream-2-tratamiento-de-segunda-linea-con-regorafenib-en-cancer-colorrectal-avanzado-con-mutacion-en-ras 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07213570/stream-2-second-line-treatment-with-regorafenib-in-advanced-ras-mutant-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07463599/seguridad-y-eficacia-de-tegavivint-en-pacientes-con-carcinoma-colorrectal-metastasico 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07463599/safety-and-efficacy-of-tegavivint-in-patients-with-metastatic-colorectal-carcinoma 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07003022/ensayo-clinico-de-fase-ii-de-cadonilimab-en-combinacion-con-agentes-antiangiogenicos-en-el-cancer-colorrectal-metastasico-dmmr-msi-h 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07003022/phase-ii-clinical-trial-of-cadonilimab-combined-with-anti-angiogenic-agents-in-metastatic-dmmr-msi-h-crc 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05283330/seguridad-y-tolerabilidad-de-212pb-dotam-grpr1-en-sujetos-adultos-con-tumores-recurrentes-o-metastasicos-que-expresan-grpr 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05283330/safety-and-tolerability-of-212pb-dotam-grpr1-in-adult-subjects-with-recurrent-or-metastatic-grpr-expressing-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07094893/agentes-anti-egfr-en-pacientes-con-cancer-colorrectal-avanzado-del-lado-derecho-con-ras-de-tipo-salvaje-y-alto-nivel-de-expresion-de-areg-ereg 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07094893/anti-egfr-agents-in-patients-with-right-sided-advanced-colorectal-cancer-with-wild-type-ras-and-areg-ereg-high-status 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06873763/nelmastobart-en-combinacion-con-trifluridina-tipiracil-y-bevacizumab-en-el-cancer-colorrectal-metastasico-recurrente 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06873763/nelmastobart-in-combination-with-trifluridine-tipiracil-and-bevacizumab-in-metastatic-recurrent-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04868877/estudio-de-fase-i-ii-que-evalua-mcla-129-un-anticuerpo-humano-bispecifico-anti-egfr-y-anti-c-met-en-pacientes-con-cancer-de-pulmon-no-microcitico-cpnm-avanzado-y-otros-tumores-solidos-tanto-en 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04868877/phase-1-2-study-evaluating-mcla-129-a-human-anti-egfr-anti-c-met-bispecific-antibody-in-advanced-nsclc-and-other-solid-tumors-alone-and-in-combination 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05848739/un-estudio-de-fase-1-2-de-st316-en-pacientes-con-tumores-solidos-avanzados-irresecables-y-metastasicos-seleccionados 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05848739/a-phase-1-2-of-st316-with-selected-advanced-unresectable-and-metastatic-solid-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07284849/un-estudio-para-evaluar-la-eficacia-y-la-seguridad-de-la-quimioterapia-estandar-y-el-bevacizumab-con-o-sin-inca33890-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-con 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07284849/a-study-to-evaluate-the-efficacy-and-safety-of-standard-of-care-chemotherapy-and-bevacizumab-with-or-without-inca33890-in-the-first-line-treatment-of-metastatic-microsatellite-stable-colorectal-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05262491/un-estudio-de-bl-b01d1-en-pacientes-con-tumor-gastrointestinal-localmente-avanzado-o-metastasico-y-otros-tumores-solidos 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05262491/a-study-of-bl-b01d1-in-patients-with-locally-advanced-or-metastatic-gastrointestinal-tumor-and-other-solid-tumor 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07229872/un-estudio-clinico-de-fase-ii-de-aipalolitovorelizumab-ql1706-en-combinacion-con-fruquintinib-para-el-tratamiento-del-cancer-colorrectal-metastasico-pmmr-mss-inmunodominante-que-ha-mostrado-falta-de 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07229872/a-phase-ii-clinical-study-of-aipalolitovorelizumab-ql1706-combined-with-fruquintinib-in-the-treatment-of-immunodominant-pmmr-mss-metastatic-colorectal-cancer-that-has-failed-second-line-or-above 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07059338/bloqueo-dual-de-egfr-her2-combinado-con-irinotecan-para-el-tratamiento-del-cancer-colorrectal-metastasico-her2-positivo 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07059338/dual-egfr-her2-blockade-combined-with-irinotecan-for-the-treatment-of-her2-positive-metastatic-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07211230/estudio-del-biobanco-de-colagenasa 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07211230/collagenase-biobank-study 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03349762/huaier-granules-para-la-prevencion-de-la-recurrencia-y-la-metastasis-en-pacientes-con-cancer-colorrectal-tras-la-cirugia-radical 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03349762/huaier-granules-for-prevention-of-recurrence-and-metastasis-of-colorectal-cancer-patients-following-radical-surgery 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT02688712/estudio-exist-de-ly2157299-galunisertib-en-cancer-de-recto 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT02688712/exist-study-of-ly2157299-galunisertib-in-rectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05080673/colonoscopia-a-los-cinco-o-diez-anos-para-1-2-polipos-adenomatosos-no-avanzados 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05080673/five-or-ten-year-colonoscopy-for-1-2-non-advanced-adenomatous-polyps 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03539822/cabozantinib-mas-durvalumab-con-o-sin-tremelimumab-en-pacientes-con-cancer-gastroesofagico-y-otras-neoplasias-gastrointestinales 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03539822/cabozantinib-plus-durvalumab-with-or-without-tremelimumab-in-patients-with-gastroesophageal-cancer-and-other-gastrointestinal-malignancies 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06952101/un-enfoque-terapeutico-multimodal-personalizado-integrado-y-adaptado-al-estadio-a-nivel-mundial-para-el-adenocarcinoma-rectal-basado-en-la-preservacion-de-organos-y-la-minima-invasion 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06952101/a-global-integrated-personalized-stage-related-multimodal-therapeutic-approach-for-rectal-adenocarcinoma-based-on-organ-sparing-and-mininvasivity 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05824975/un-estudio-para-evaluar-la-seguridad-y-la-actividad-terapeutica-de-gi-102-como-agente-unico-y-en-combinacion-con-farmacos-antineoplasicos-convencionales-pembrolizumab-o-trastuzumab-deruxtecan-t-dxd 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05824975/a-study-to-evaluate-the-safety-and-therapeutic-activity-of-gi-102-as-a-single-agent-and-in-combination-with-conventional-anti-cancer-drugs-pembrolizumab-or-trastuzumab-deruxtecan-t-dxd-in-patients 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06131840/un-estudio-de-sgn-ceacam5c-en-adultos-con-tumores-solidos-avanzados 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06131840/a-study-of-sgn-ceacam5c-in-adults-with-advanced-solid-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03678883/9-ing-41-en-pacientes-con-canceres-avanzados 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03678883/9-ing-41-in-patients-with-advanced-cancers 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04494945/identificacion-y-atencion-a-pacientes-con-sindromes-hereditarios-de-cancer 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04494945/identifying-and-caring-for-individuals-with-inherited-cancer-syndrome 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07124000/destiny-pantumour04 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05726864/un-estudio-de-eli-002-7p-en-sujetos-con-tumores-solidos-con-mutaciones-en-kras-nras 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05726864/a-study-of-eli-002-7p-in-subjects-with-kras-nras-mutated-solid-tumors 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07636785/un-estudio-de-fase-1-y-2-de-vmd-102-en-carcinoma-hepatocelular-y-otros-tumores-solidos 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT07636785/a-phase-1-and-2-study-of-vmd-102-in-hepatocellular-carcinoma-and-other-solid-tumors 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06997497/un-estudio-clinico-de-calderasib-mk-1084-con-terapia-dirigida-y-quimioterapia-en-pacientes-con-cancer-colorrectal-mk-1084-012-kandlelit-012 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06997497/a-clinical-study-of-calderasib-mk-1084-with-targeted-therapy-and-chemotherapy-in-people-with-colorectal-cancer-mk-1084-012-kandlelit-012 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07646106/the-0504-en-pacientes-con-tumores-solidos 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT07646106/the-0504-in-patients-with-solid-tumors 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT03432806/un-estudio-de-imagenes-muestras-de-sangre-y-tejido-para-guiar-el-tratamiento-del-cancer-de-colon-y-los-tumores-hepaticos-relacionados 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT03432806/a-study-of-imaging-blood-and-tissue-samples-to-guide-treatment-of-colon-cancer-and-related-liver-tumors 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT06342401/deteccion-temprana-del-cancer-colorrectal-en-pacientes-jovenes 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT06342401/early-onset-colorectal-cancer-detection 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT05038254/mejora-de-la-gestion-de-los-sintomas-en-el-ambito-ambulatorio-para-reducir-las-visitas-a-los-servicios-de-atencion-aguda-debidas-a-acontecimientos-adversos-relacionados-con-la-quimioterapia 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT05038254/enhanced-outpatient-symptom-management-to-reduce-acute-care-visits-due-to-chemotherapy-related-adverse-events 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04999761/estudio-de-la-plataforma-ab122 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04999761/ab122-platform-study 2026-06-23 weekly 0.7 https://crcwarriors.org/ensayo/NCT04963283/estudio-de-cabozantinib-y-nivolumab-en-cancer-colorrectal-metastasico-refractario-y-con-estabilidad-de-microsatelites-mss 2026-06-23 weekly 0.6 https://crcwarriors.org/ensayo/NCT04963283/study-of-cabozantinib-and-nivolumab-in-refractory-metastatic-microsatellite-stable-mss-colorectal-cancer 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/oxaliplatin 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/uracil 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/uracil/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/fluorouracil 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/fluorouracil/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/5-fluorouracil 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/5-fluorouracil/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/leucovorin 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/leucovorin/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/capecitabine 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/capecitabine/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/irinotecan 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/irinotecan/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cetuximab 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/cetuximab/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/pembrolizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pembrolizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/met 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/met/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/panitumumab 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/panitumumab/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/nivolumab 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/nivolumab/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/regorafenib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/regorafenib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/rego 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/rego/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/tislelizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tislelizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/fruquintinib 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/fruquintinib/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamid 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamid/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/atezolizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/atezolizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cisplatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cisplatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/carboplatin 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/carboplatin/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/durvalumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/durvalumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipilimumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ipilimumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gemcitabine 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/gemcitabine/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/sintilimab 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/sintilimab/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/pemetrexed 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/pemetrexed/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/celecoxib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/celecoxib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cele 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/cele/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/s-1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/s-1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aldesleukin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aldesleukin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fludarabine 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fludarabine/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aspirin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aspirin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fulvestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fulvestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/encorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/encorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/docetaxel 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/docetaxel/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aflibercept 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aflibercept/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/binimetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/binimetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trametinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trametinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/palbociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/palbociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tori 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tori/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/erlotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erlotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/everolimus 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/everolimus/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nab-paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/nab-paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/toripalimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/toripalimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cadonilimab 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/cadonilimab/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/balstilimab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/balstilimab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/botensilimab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/botensilimab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/serplulimab 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/serplulimab/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/vemurafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/vemurafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/avelumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avelumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cemiplimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cemiplimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sargramostim 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sargramostim/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/metformin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/metformin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/olaparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/olaparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/temozolomide 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/temozolomide/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxteca 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxteca/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dostarlimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dostarlimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/adagrasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adagrasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexamethasone 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/dexamethasone/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/tremelimumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tremelimumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cabozantinib 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/cabozantinib/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/adebrelimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adebrelimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/peg 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/peg/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tucatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tucatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/apatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/apatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/lidocaine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lidocaine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abemaciclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abemaciclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camrelizumab 2026-04-16 weekly 0.7 https://crcwarriors.org/medicamento/camrelizumab/ensayos 2026-04-16 weekly 0.6 https://crcwarriors.org/medicamento/ivonescimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ivonescimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/metronidazole 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/metronidazole/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/mitomycin 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/mitomycin/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/raltitrexed 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/raltitrexed/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pertuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pertuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ribociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ribociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amg/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tipiracil 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tipiracil/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ramucirumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ramucirumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/envafolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/envafolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sotorasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sotorasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selumetinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selumetinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/letrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/letrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dabrafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dabrafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sunitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/sunitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/ql1706 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ql1706/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tas 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tas/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak112 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak112/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hydroxychloroquine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hydroxychloroquine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osimertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/osimertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gefitinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gefitinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bortezomib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/bortezomib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/lapatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/lapatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/axitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/axitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/filgrastim 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/filgrastim/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/lenvatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/lenvatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/infliximab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/infliximab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/amivantamab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amivantamab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vandetanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vandetanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cediranib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cediranib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/chidamide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/chidamide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sulindac 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sulindac/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dasatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dasatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphala 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/melphala/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vorinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/vorinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vorinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vorinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphalan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/melphalan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/midazolam 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/midazolam/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/iparomlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/iparomlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/afatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/afatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tuvonralimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tuvonralimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cobimetinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cobimetinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/doxorubicin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/doxorubicin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/indocyanine+green 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indocyanine+green/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/retifanlimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/retifanlimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tegafu 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tegafu/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sasanlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sasanlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/temsirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/temsirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zanidatamab 2026-06-09 weekly 0.7 https://crcwarriors.org/medicamento/zanidatamab/ensayos 2026-06-09 weekly 0.6 https://crcwarriors.org/medicamento/veliparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/veliparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/azacitidine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/azacitidine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tegafur 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tegafur/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enzalutamide 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/enzalutamide/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/other 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/other/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/g17dt 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/g17dt/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eflornithine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eflornithine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bkm120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bkm120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/moviprep 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/moviprep/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/g17d 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g17d/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-21822 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-21822/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/entinostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entinostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nw-301v 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/nw-301v/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/adc 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adc/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pdr001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pdr001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tno155 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tno155/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx10 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hlx10/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pumitamig 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/pumitamig/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/pazopanib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pazopanib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/t3011 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/t3011/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/anlotinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/anlotinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/hrs-4642 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hrs-4642/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nktr 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nktr/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/omeprazole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/omeprazole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6236 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6236/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/crizotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/crizotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexmedetomidine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dexmedetomidine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tocilizumab 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/tocilizumab/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/fianlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/fianlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etrumadenant 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etrumadenant/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ropivacaine 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/ropivacaine/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/decitabine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/decitabine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ts-1 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ts-1/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/shr-8068 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-8068/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/nintedanib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nintedanib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/lenalidomide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lenalidomide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/methotrexate 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/methotrexate/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/itraconazole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/itraconazole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sym004 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym004/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/penpulimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/penpulimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/propofol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/propofol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine-tipiracil 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine-tipiracil/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ruxolitinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/ruxolitinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/lorigerlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lorigerlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/spartalizumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/spartalizumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nw-301d 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/nw-301d/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/riluzole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/riluzole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tiragolumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tiragolumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pegfilgrastim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pegfilgrastim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/saline 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/saline/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/nktr- 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/nktr-/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/sevoflurane 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sevoflurane/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/daraxonrasib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/daraxonrasib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/epacadostat 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/epacadostat/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/imatinib 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/imatinib/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/tivozanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tivozanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sgm-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgm-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbi608 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bbi608/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bi-1701963 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bi-1701963/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bp102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bp102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pf-07220060 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07220060/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imiquimod 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imiquimod/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/naliri 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/naliri/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/abbv-400 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abbv-400/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hmn14 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hmn14/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/allostim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/allostim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/neratinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/neratinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/radiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/radiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/inavolisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inavolisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ganitumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ganitumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/e7386 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7386/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/semaxanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/semaxanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osi-906 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/osi-906/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/rmc-9805 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-9805/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etbx-011 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-011/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bupivacain 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bupivacain/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hdm201 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/hdm201/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hs-20093 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20093/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tucidinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tucidinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/indomethacin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indomethacin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tucidinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tucidinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/doxycycline 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/doxycycline/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enadenotucirev 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enadenotucirev/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/regn7075 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/regn7075/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/defactinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/defactinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/romidepsi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/calderasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/calderasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg-655 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-655/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mk-2206 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mk-2206/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/prednisone 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/prednisone/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/eniluracil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eniluracil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vedolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vedolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/indomethaci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/indomethaci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nilotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/nilotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plenvu 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plenvu/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pucotenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pucotenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastati 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastati/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selpercatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/selpercatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/romidepsin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gvax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gvax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/panobinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/panobinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipir 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipir/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/relatlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/relatlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m9140 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/m9140/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mcla-129 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mcla-129/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/flucytosine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/flucytosine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/talazoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/talazoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etrolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/etrolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nimotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nimotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cs-1008 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cs-1008/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dalotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dalotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selinexo 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexo/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ulixertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ulixertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vismodegib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vismodegib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zimberelimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/zimberelimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/egfr 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/egfr/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/selinexor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amg-479 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-479/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/niraparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/niraparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/incb001158 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb001158/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gv20-0251 2026-06-04 weekly 0.7 https://crcwarriors.org/medicamento/gv20-0251/ensayos 2026-06-04 weekly 0.6 https://crcwarriors.org/medicamento/shr-a1811 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/shr-a1811/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibf-1120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bibf-1120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/n-803 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/n-803/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7820 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7820/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abx-egf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/abx-egf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gsk5764227 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gsk5764227/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/onvansertib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/onvansertib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pd-0325901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pd-0325901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemoradiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemoradiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/brivanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/brivanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sg001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sg001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclosporine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyclosporine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ner1006 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ner1006/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/alectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/panobinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/panobinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10370 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10370/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mw4911 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mw4911/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/neomyci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomyci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/maraviroc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/maraviroc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eribulin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eribulin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/magrolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/magrolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbo-10203 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/bbo-10203/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/rnk08954 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/rnk08954/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/ci-1040 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ci-1040/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nis793 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nis793/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cv301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cv301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ivosidenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ivosidenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imc-a12 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imc-a12/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tinzaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/napabucasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/napabucasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10502 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10502/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rimiducid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rimiducid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pralsetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pralsetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/calmangafodipir 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/calmangafodipir/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gdc-1971 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gdc-1971/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/reolysi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/conatumumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/conatumumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ceralasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ceralasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/masitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/masitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/d-1553 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/d-1553/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rec-4881 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/rec-4881/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/budigalimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/budigalimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bms-986340 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986340/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inc280 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inc280/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/kd018 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/kd018/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/arfolitixorin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/arfolitixorin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sgn1 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/sgn1/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/ca102n 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ca102n/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/udenafil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/udenafil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/volrustomig 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/volrustomig/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/foxy-5 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/foxy-5/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cmab009 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cmab009/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ibi363 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ibi363/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/anastrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/anastrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amt2003 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/amt2003/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/exemestane 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/exemestane/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/alt-803 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/alt-803/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imlunestrant 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/imlunestrant/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/pro95780 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/pro95780/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/azd5305 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/azd5305/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak119 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak119/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7070 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7070/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elimusertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/elimusertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pirfenidone 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/pirfenidone/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enzastaurin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/enzastaurin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nv1020 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nv1020/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/entrectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entrectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibw-2992 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibw-2992/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/erdafitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erdafitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ssgj-612 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/ssgj-612/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/dovitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/dovitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enoxaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enoxaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/denosumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/denosumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vatalanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vatalanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fmt 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/fmt/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/floxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/floxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaba 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaba/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/xilonix 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/xilonix/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/artesunate 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/artesunate/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bms-986016 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986016/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bli850 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bli850/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-20117 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20117/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx208 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hlx208/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/fluzoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fluzoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/capivasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/capivasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/copanlisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/copanlisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rezatapop 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapop/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/leflunomide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/leflunomide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipatasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ipatasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camizestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/camizestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/larotrectinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/larotrectinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dato-dxd 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dato-dxd/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rmc-4630 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-4630/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bi-765049 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bi-765049/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dulanermin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dulanermin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cannabidiol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cannabidiol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ridaforolimus 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ridaforolimus/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ga-nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/ga-nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/naproxen 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxen/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/lubiprostone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/lubiprostone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/fleet 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/fleet/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/neomycin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomycin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nalirifox 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/nalirifox/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/bupivacaine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bupivacaine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ufox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ufox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dsp107 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dsp107/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-4000 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-4000/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/oleclumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/oleclumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/trk-950 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/trk-950/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hua33 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hua33/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bisacodyl 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bisacodyl/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hf50 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/hf50/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/jab-3312 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jab-3312/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bgb-43395 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/bgb-43395/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/cb-839 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cb-839/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pm8002 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pm8002/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pemigatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pemigatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gastrografin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gastrografin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/plerixafo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/plerixafo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sgi-110 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgi-110/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-151 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-151/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/carmustine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/carmustine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abiraterone 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/abiraterone/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/ompenaclid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ompenaclid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-398 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-398/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaban 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaban/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/js207 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/js207/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/thalidomide 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/thalidomide/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/il2 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/il2/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/hsk42360 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/hsk42360/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/silymarin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/silymarin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/desflurane 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/desflurane/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamyci 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamyci/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/utidelone 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/utidelone/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/loperamide 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/loperamide/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gh21 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gh21/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/si-b003 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b003/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-051 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-051/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/can04 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/can04/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-061 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-061/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-6301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-6301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-c901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-c901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-r902 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-r902/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nc410 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nc410/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/a166 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/a166/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rifaximi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3214996 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ly3214996/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamycin 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamycin/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/avzo-021 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/avzo-021/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/famitinib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/famitinib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bmx-001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bmx-001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-1701 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-1701/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/prexasertib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prexasertib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tovorafenib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tovorafenib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/flox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/flox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sph5030 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sph5030/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plerixafor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plerixafor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/simvastatin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/simvastatin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/resveratrol 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/resveratrol/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cm-24 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cm-24/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cp-675 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cp-675/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/g-csf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g-csf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gemnabp 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gemnabp/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rezatapopt 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapopt/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/zanzalintinib 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/zanzalintinib/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/ono-4578 2026-04-18 weekly 0.7 https://crcwarriors.org/medicamento/ono-4578/ensayos 2026-04-18 weekly 0.6 https://crcwarriors.org/medicamento/piritramid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/piritramid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-121 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-121/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/curcumin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/curcumin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/bms-986504 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/bms-986504/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/dtx 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/dtx/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/pds0101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds0101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/acetaminophen 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/acetaminophen/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m7824 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/m7824/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/silymari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/silymari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/simvastati 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/simvastati/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/golytely 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/golytely/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bl-b01d1 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bl-b01d1/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/byl719 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/byl719/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/aipalolitovorelizumab 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/aipalolitovorelizumab/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mgd007 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mgd007/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vactosertib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vactosertib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/sym021 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym021/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/xl092 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/xl092/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adalimumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/adalimumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/incb106385 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb106385/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/interferon 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/interferon/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3023414 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/ly3023414/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tegavivint 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tegavivint/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/rp2 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/rp2/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovori 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovori/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mesalamine 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/mesalamine/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tg6002 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tg6002/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-23e73 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-23e73/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/yl-17231 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/yl-17231/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/alpelisib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alpelisib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ropidoxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ropidoxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cyad-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyad-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/glutamine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/glutamine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/kqb198 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/kqb198/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/lazertinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/lazertinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/ezabenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ezabenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngm438 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngm438/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/isis 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/isis/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vs-7375 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/vs-7375/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/epinephrine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/epinephrine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/propranolol 2026-05-01 weekly 0.7 https://crcwarriors.org/medicamento/propranolol/ensayos 2026-05-01 weekly 0.6 https://crcwarriors.org/medicamento/naproxe 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxe/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nsaid 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nsaid/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sc-201 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sc-201/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tegavivi 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/tegavivi/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/ethynyluracil 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ethynyluracil/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/avx701 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avx701/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzapari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tinzapari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hmbd-001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hmbd-001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/surufatinib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/surufatinib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/ixabepilone 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ixabepilone/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selenium 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/selenium/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hlx07 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/hlx07/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/jdq443 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jdq443/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tazemetostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tazemetostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pds01adc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds01adc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/krn330 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/krn330/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inca33890 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/inca33890/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ensartinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/ensartinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6291 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6291/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovorin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovorin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/pf-07799933 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07799933/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rifaximin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jx-594 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jx-594/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/reolysin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tas-102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tas-102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/star0602 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/star0602/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ferumoxytol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ferumoxytol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jmt101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jmt101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bl-m17d1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bl-m17d1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/b1962 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/b1962/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cibisatamab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cibisatamab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elironrasib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/elironrasib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/obinutuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/obinutuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ibrutinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ibrutinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngr-htnf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngr-htnf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/venetoclax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/venetoclax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/si-b001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gm-ct-01 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/gm-ct-01/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/napabucasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/napabucasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/regimen/folfox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfox-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-panitumumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capecitabine-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/pembrolizumab-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/encorafenib-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trastuzumab-pertuzumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trifluridine-tipiracil 2026-02-13 monthly 0.8 https://crcwarriors.org/articulo/2414/seguridad-y-eficacia-de-una-estrategia-de-terapia-neoadyuvante-total-tipo-sandwich-para-el-cancer-colorrectal-distal-localmente-avanzado-de-bajo-riesgo-resultados-del-ensayo-tess-de-fase-ii 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2414/safety-and-efficacy-of-a-sandwich-total-neoadjuvant-therapy-strategy-for-low-risk-distal-locally-advanced-rectal-cancer-results-from-the-tess-phase-ii-trial 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2391/efecto-de-uno-o-dos-ciclos-de-inmunoterapia-combinada-con-nivolumab-e-ipilimumab-en-pacientes-con-cancer-colorrectal-con-deficiencia-en-la-reparacion-de-errores-reset-r-resultados-preliminares-de-un 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2391/effect-of-one-or-two-cycles-of-dual-immunotherapy-with-nivolumab-and-ipilimumab-in-patients-with-mismatch-repair-deficient-rectal-cancer-reset-r-interim-results-from-a-multicentre-single-arm-phase-2 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2379/dirigirse-a-la-separacion-de-fases-liquido-liquido-de-aven-en-el-cancer-colorrectal-hallazgos-derivados-de-una-sonda-quimica-basada-en-raddeanina-a 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2379/targeting-aven-liquid-liquid-phase-separation-in-colorectal-cancer-insights-from-a-raddeanin-a-based-chemical-probe 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2374/los-subtipos-moleculares-consensuados-proporcionan-informacion-para-la-seleccion-del-agente-en-la-quimioterapia-hipertermia-intraperitoneal-hipec-en-las-metastasis-peritoneales-del-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2374/consensus-molecular-subtypes-inform-hipec-agent-selection-in-colorectal-cancer-peritoneal-metastases 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2373/el-papel-pronostico-de-la-inflamacion-postoperatoria-tras-la-reseccion-minimamente-invasiva-del-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2373/the-prognostic-role-of-postoperative-inflammation-after-minimally-invasive-resection-for-colorectal-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2341/vasculatura-funcional-en-organoides-tumorales-facilitando-la-medicina-de-precision-en-oncologia 2026-06-12 monthly 0.5 https://crcwarriors.org/articulo/2341/functional-vasculature-in-tumor-organoids-enabling-precision-medicine-in-oncology 2026-06-12 monthly 0.5 https://crcwarriors.org/articulo/2327/la-carga-mutacional-tumoral-evaluada-en-tejidos-y-sangre-predice-la-respuesta-al-tratamiento-con-inhibidores-de-pd-1-en-el-carcinoma-de-celulas-escamosas-de-cabeza-y-cuello-una-revision-sistematica-y 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2327/tissue-and-blood-based-tumor-mutational-burden-predicts-treatment-response-to-pd-1-blockade-in-head-and-neck-squamous-cell-carcinoma-a-systematic-review-and-meta-analysis 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2294/superacion-de-la-resistencia-inmune-condicional-en-el-cancer-colorrectal-mss-y-pmmr-un-modelo-de-secuenciacion-escalonada-para-la-inmunoterapia 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2294/overcoming-conditional-immune-resistance-in-mss-and-pmmr-colorectal-cancer-a-sequential-gating-framework-for-immunotherapy 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2293/el-receptor-de-vitamina-d-en-los-tumores-una-revision-de-los-mecanismos-biologicos-los-posibles-usos-terapeuticos-y-los-valores-pronosticos 2026-06-15 monthly 0.5 https://crcwarriors.org/articulo/2293/vitamin-d-receptor-in-tumors-a-review-of-biological-mechanisms-therapeutic-potentials-and-prognostic-values 2026-06-15 monthly 0.5 https://crcwarriors.org/articulo/2280/la-ferroptosis-en-el-cancer-colorrectal-mecanismos-moleculares-y-la-interaccion-reguladora-con-posibles-aplicaciones-terapeuticas-revision 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2280/ferroptosis-in-colorectal-cancer-molecular-mechanisms-and-regulatory-crosstalk-with-therapeutic-prospects-review 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2261/quimiorradioterapia-adyuvante-frente-a-reseccion-total-del-meso-recto-complementaria-tras-reseccion-local-para-el-cancer-de-recto-en-estadio-temprano-tesar-un-ensayo-multicentrico-aleatorizado 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2261/adjuvant-chemoradiotherapy-versus-completion-total-mesorectal-excision-after-local-excision-for-early-rectal-cancer-tesar-a-multicentre-randomised-controlled-phase-3-non-inferiority-trial 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2257/la-neferina-al-potenciar-la-formula-shenling-baizhu-tang-refuerza-la-terapia-anti-pd-1-en-las-metastasis-hepaticas-del-cancer-colorrectal-a-traves-de-la-reprogramacion-lipidica-mediada-por-cyp2e1-ppar 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2257/neferine-enhanced-shenling-baizhu-tang-potentiates-anti-pd-1-therapy-in-colorectal-cancer-liver-metastasis-via-cyp2e1-ppar-mediated-lipid-reprogramming 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2232/la-plataforma-de-oncologia-de-precision-funcional-de-organoides-de-cancer-colorrectal-con-mutacion-braf-v600e-predice-la-respuesta-al-tratamiento-y-revela-la-inmunogenicidad-mediada-por-rnf43 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2232/functional-precision-oncology-platform-of-braf-v600e-mutated-colorectal-cancer-organoids-predicts-therapy-response-and-reveals-rnf43-mediated-immunogenicity 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2158/evaluacion-del-ct-adn-y-el-estado-mutacional-en-la-biopsia-liquida-de-pacientes-con-cancer-colorrectal-metastasico 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2158/evaluation-of-ct-dna-and-mutational-status-in-liquid-biopsy-of-patients-with-metastatic-colorectal-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2038/sotorasib-mas-panitumumab-y-5-fluorouracilo-en-el-tratamiento-de-primera-linea-de-pacientes-con-cancer-colorrectal-irresecable-con-mutacion-kras-g12c-que-no-son-aptos-para-quimioterapia-combinada 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2038/sotorasib-plus-panitumumab-and-5-fluorouracil-in-first-line-treatment-of-patients-with-unresectable-kras-g12c-mutated-colorectal-cancer-unfit-for-a-doublet-triplet-chemotherapy-engic-01-prodige-107 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/1996/los-conjugados-peptido-farmaco-que-contienen-la-carga-antimitotica-ahx-da1-logran-una-potente-actividad-antitumoral-en-modelos-in-vivo-de-canceres-con-amplificacion-de-her2-positivos-para-egfr-y-con 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/1996/peptide-drug-conjugates-bearing-an-antimitotic-ahx-da1-payload-achieve-potent-antitumor-activity-in-her2-amplified-and-egfr-positive-kras-mutant-cancers-in-vivo 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/1963/analisis-basado-en-secuenciacion-de-siguiente-generacion-del-espectro-de-mutaciones-geneticas-en-cancer-colorrectal-un-estudio-de-gran-escala-de-un-unico-centro-del-sureste-de-china-con-comparacion 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/1963/next-generation-sequencing-based-analysis-of-the-genetic-mutation-spectrum-in-colorectal-cancer-a-large-single-center-study-from-southeast-china-with-cross-population-comparison 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/1959/resumen-visual-de-aso-la-combinacion-de-mutaciones-en-ras-y-smad4-junto-con-la-inestabilidad-de-microsatelites-predice-los-resultados-en-metastasis-pulmonares-de-cancer-colorrectal-tratadas-con 2026-06-11 monthly 0.5 https://crcwarriors.org/articulo/1959/aso-visual-abstract-combined-ras-and-smad4-mutations-and-microsatellite-instability-predict-outcomes-in-colorectal-lung-metastases-treated-with-image-guided-thermal-ablation 2026-06-11 monthly 0.5 https://crcwarriors.org/articulo/1922/runx1-activa-directamente-a-wnt2-para-orquestar-la-reprogramacion-de-los-macrofagos-asociados-al-tumor-en-el-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/1922/runx1-directly-activates-wnt2-to-orchestrate-tumor-associated-macrophage-reprogramming-in-colorectal-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/1912/mutaciones-combinadas-de-ras-y-smad4-e-inestabilidad-de-microsatelites-predicen-los-resultados-en-metastasis-pulmonares-colorrectales-tratadas-con-ablacion-termica-guiada-por-imagen 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/1912/combined-ras-and-smad4-mutations-and-microsatellite-instability-predict-outcomes-in-colorectal-lung-metastases-treated-with-image-guided-thermal-ablation 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/1698/displasia-en-lesiones-serradas-sesiles-frecuencia-variabilidad-interobservador-y-valor-anadido-de-la-inmunohistoquimica 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/1698/dysplasia-in-sessile-serrated-lesions-frequency-interobserver-variability-and-added-value-of-immunohistochemistry 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/1623/las-probioticos-ingenierizados-despojados-de-metionina-promueven-la-inmunoterapia-con-anticuerpos-anti-pd-l1-al-activar-el-camino-sting 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/1623/methionine-depleting-engineered-probiotics-promote-pd-l1-antibody-immunotherapy-by-activating-the-sting-pathway 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/1607/aplicar-reguladores-nanomimeticos-para-fototerapia-in-situ-y-regulacion-de-lactato-con-el-fin-de-amplificar-la-terapia-inmunitaria-cuproptosis 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/1607/harnessing-biomimetic-nano-regulators-for-in-situ-photothermia-and-lactate-regulation-to-amplify-cuproptosis-immunotherapy 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/1189/irs2-como-factor-impulsor-y-diana-terapeutica-en-las-metastasis-cerebrales-del-cancer-colorrectal-una-revision-sistematica-de-la-evidencia-mecanicista-y-traslacional 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/1189/irs2-as-a-driver-and-therapeutic-target-in-brain-metastases-from-colorectal-cancer-a-systematic-review-of-mechanistic-and-translational-evidence 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2430/el-bloqueo-de-los-puntos-de-control-inmunitario-potencia-la-inmunidad-antitumoral-inducida-por-la-quimioterapia-depletor-de-linfocitos-al-expandir-los-clones-de-celulas-t-citotoxicas-cd8 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2430/immune-checkpoint-blockade-augments-lymphodepleting-chemotherapy-induced-antitumor-immunity-by-expanding-effector-cd8-t-cell-clones 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2429/redes-regulatorias-multidimensionales-de-la-resistencia-a-los-farmacos-en-el-cancer-colorrectal-desde-los-mecanismos-moleculares-hasta-nuevas-estrategias-terapeuticas 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2429/multidimensional-regulatory-networks-of-drug-resistance-in-colorectal-cancer-from-molecular-mechanisms-to-novel-therapeutic-counterstrategies 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2428/estratificacion-diagnostica-de-globo-h-e-identificacion-de-dusp14-como-un-posible-blanco-terapeutico-en-el-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2428/globo-h-diagnostic-stratification-and-identification-of-dusp14-as-a-candidate-target-in-colorectal-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2427/tener-en-cuenta-la-ubicacion-del-tumor-es-fundamental-para-una-interpretacion-precisa-de-los-resultados-de-la-biopsia-liquida-en-el-cancer-colorrectal-metastasico 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2427/considering-tumour-sidedness-is-critical-for-accurate-interpretation-of-liquid-biopsy-results-in-metastatic-colorectal-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2426/evaluacion-de-pegenzileukin-sar444245-thor-707-en-combinacion-con-pembrolizumab-o-cetuximab-en-cancer-gastrointestinal-metastasico-avanzado-el-estudio-pegathor-de-fase-ii 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2426/evaluating-pegenzileukin-sar444245-thor-707-in-combination-with-pembrolizumab-or-cetuximab-in-advanced-metastatic-gastrointestinal-cancer-the-pegathor-phase-2-study 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2425/el-eje-adar1-circrab5a-bip-regula-la-resistencia-a-la-radioterapia-en-el-cancer-colorrectal-mediante-la-coordinacion-de-la-autofagia-protectora-y-la-apoptosis 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2425/adar1-circrab5a-bip-axis-governs-radiotherapy-resistance-in-colorectal-cancer-through-coordinating-protective-autophagy-and-apoptosis 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2424/mecanismos-y-estrategias-emergentes-para-superar-la-resistencia-a-la-inmunoterapia-en-tumores-frios-del-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2424/mechanisms-and-emerging-strategies-to-overcome-immunotherapy-resistance-in-cold-tumours-of-colorectal-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2422/la-gemcitabina-aumento-la-sensibilidad-del-cancer-colorrectal-a-la-terapia-anti-pd-l1-al-promover-la-lactilacion 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2422/gemcitabine-enhanced-the-sensitivity-of-colorectal-cancer-to-anti-pd-l1-therapy-by-promoting-lactylation 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2421/la-insuficiente-ferroptosis-en-las-celulas-tumorales-inducidas-por-la-radiacion-favorece-la-generacion-de-celulas-treg-lo-que-induce-resistencia-a-la-radioterapia 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2421/insufficient-ferroptosis-in-radiation-induced-tumor-cells-promote-treg-cell-generation-to-induce-radiotherapy-resistance 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2420/la-cefarantina-induce-la-muerte-celular-inmunogenica-en-tumores-solidos-al-suprimir-la-expresion-de-la-poli-adp-ribosa-polimerasa-1-mediada-por-la-proteina-quinasa-c-zeta-y-presenta-una-accion 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2420/cepharanthine-triggers-immunogenic-cell-death-in-solid-tumors-by-suppressing-protein-kinase-c-zeta-mediated-poly-adp-ribose-polymerase-1-expression-and-synergizes-with-immunotherapy 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2419/evaluacion-de-la-carga-de-los-canceres-asociados-al-vph-en-brasil-tendencias-de-hospitalizacion-y-mortalidad-de-2011-a-2019 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2419/assessing-the-burden-of-hpv-associated-cancers-in-brazil-hospitalization-and-mortality-trends-from-2011-to-2019 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2418/analisis-conjunto-de-2-ensayos-clinicos-sobre-quimioinmunoterapia-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-microsatelites-estables-estudios-meditreme-y-metimmox 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2418/pooled-analysis-of-2-clinical-trials-of-first-line-chemoimmunotherapy-for-metastatic-microsatellite-stable-colorectal-cancer-meditreme-and-metimmox-studies 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2415/adcs-para-el-carcinoma-colorrectal-analisis-de-la-evidencia-clinica-para-la-innovacion-en-el-diseno-molecular 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2415/adcs-for-colorectal-carcinoma-decoding-clinical-evidence-for-molecular-design-innovation 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2413/mir-31-como-biomarcador-predictivo-de-la-eficacia-del-cetuximab-en-pacientes-con-cancer-colorrectal-metastasico-revision-sistematica 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2413/mir-31-as-a-predictive-biomarker-of-cetuximab-efficacy-in-metastatic-colorectal-cancer-patients-systematic-review 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2411/una-revision-sistematica-exhaustiva-de-la-patogenia-molecular-de-los-canceres-del-sistema-digestivo-2013-2025 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2411/a-systematic-scoping-review-of-the-molecular-pathogenesis-of-digestive-system-cancers-2013-2025 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2410/sistema-de-administracion-de-vesiculas-extracelulares-tumorales-programado-mediante-ultrasonido-para-una-terapia-dual-inmuno-epigenetica-contra-la-metastasis-del-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2410/ultrasound-programmable-tumor-extracellular-vesicles-delivery-system-for-dual-immune-epigenetic-therapy-against-colorectal-cancer-metastasis 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2409/avances-en-el-trasplante-hepatico-para-tumores-hepaticos-malignos 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2409/advances-in-liver-transplantation-for-hepatic-malignancies 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2408/los-fibroblastos-asociados-al-cancer-postn-forman-una-barrera-similar-a-una-fortaleza-que-contribuye-a-la-resistencia-a-la-inmunoterapia-en-el-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2408/postn-cancer-associated-fibroblasts-forming-fortress-like-barrier-to-mediate-immunotherapy-resistance-in-colorectal-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2407/un-nuevo-conjugado-anticuerpo-farmaco-disenado-para-dirigirse-a-b7-h3-demuestra-una-mayor-eficacia-terapeutica-en-una-amplia-gama-de-canceres 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2407/a-newly-designed-antibody-drug-conjugate-targeting-b7-h3-demonstrates-enhanced-therapeutic-efficacy-across-a-spectrum-of-cancers 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2406/respuesta-completa-sostenida-al-tratamiento-con-la-plataforma-tmep-ci-m-en-un-cancer-de-pulmon-de-celulas-pequenas-refractario-con-metastasis-en-el-tronco-encefalico-informe-de-un-caso-con-mas-de-20 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2406/sustained-complete-response-to-tmep-ci-m-platform-in-refractory-small-cell-lung-cancer-with-brainstem-metastasis-a-case-report-with-over-20-months-of-disease-free-survival 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2405/eficacia-y-seguridad-comparativas-de-los-tratamientos-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-ras-tipo-salvaje-una-revision-sistematica-y-un-metaanalisis-de-red 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2405/comparative-efficacy-and-safety-of-first-line-treatments-for-ras-wild-type-metastatic-colorectal-cancer-a-systematic-review-and-network-meta-analysis 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2404/renovacion-del-aire-en-el-dormitorio-como-terapia-adyuvante-antiinflamatoria-en-supervivientes-de-cancer-protocolo-para-la-serie-de-ensayos-aleatorizados-controlados-con-placebo-breaths-n-of-1 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2404/in-bedroom-renewed-air-as-anti-inflammatory-adjuvant-therapy-in-cancer-survivors-protocol-for-the-randomised-placebo-controlled-breaths-n-of-1-trial-series 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2403/resistencia-a-la-inmunoterapia-en-el-cancer-colorrectal-estrategias-terapeuticas-y-enfoques-guiados-por-biomarcadores 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2403/immunotherapy-resistance-in-colorectal-cancer-therapeutic-strategies-and-biomarker-guided-approaches 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2401/factores-de-riesgo-tipos-de-cancer-y-significado-pronostico-del-segundo-cancer-primario-tras-el-cancer-colorrectal-de-inicio-temprano-intermedio-y-tardio-un-estudio-retrospectivo-en-un-centro 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2401/risk-factors-cancer-types-and-prognostic-significance-of-second-primary-cancer-after-early-intermediate-and-late-onset-colorectal-cancer-a-retrospective-study-in-a-chinese-high-volume-cancer-center 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2400/erlotinib-mas-bevacizumab-en-tumores-solidos-metastasicos-con-amplificacion-de-egfr-resultados-del-estudio-kosmos-i-ii-que-evalua-la-terapia-guiada-por-el-perfilado-molecular-en-canceres-avanzados 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2400/erlotinib-plus-bevacizumab-in-egfr-amplified-metastatic-solid-tumors-results-from-the-kosmos-i-ii-study-of-molecular-profiling-guided-therapy-in-advanced-cancers 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2399/interaccion-entre-las-vias-de-muerte-celular-metabolica-en-el-cancer-colorrectal-implicaciones-para-la-terapia-de-precision 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2399/crosstalk-of-metabolic-cell-death-pathways-in-colorectal-cancer-implications-for-precision-therapy 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2398/evaluacion-de-la-mesotelina-como-un-blanco-inmunoterapeutico-para-las-celulas-t-endogenas 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2398/evaluating-mesothelin-as-an-immunotherapeutic-target-for-endogenous-t-cells 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2397/la-edicion-del-arn-a-nivel-de-celula-unica-identifica-a-adar1-en-las-celulas-t-como-un-regulador-clave-del-agotamiento-inmunitario-y-la-resistencia-anti-pd-1-en-el-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2397/single-cell-rna-editing-identifies-t-cell-adar1-as-a-key-regulator-of-immune-exhaustion-and-anti-pd-1-resistance-in-colorectal-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2393/diferencias-raciales-y-etnicas-en-los-resultados-del-cribado-del-cancer-de-prostata-en-los-estados-unidos-un-analisis-secundario-del-ensayo-sobre-el-cancer-de-prostata-pulmon-colon-y-ovario 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2393/racial-and-ethnic-differences-in-prostate-cancer-screening-outcomes-in-the-united-states-a-secondary-analysis-of-the-prostate-lung-colorectal-and-ovarian-cancer-trial 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2392/caracteristicas-moleculares-de-pacientes-chinos-con-cancer-colorrectal-y-inestabilidad-de-microsatelites 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2392/molecular-characteristics-of-chinese-colorectal-cancer-patients-with-microsatellite-instability 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2390/el-analisis-transcriptomico-de-celulas-individuales-revela-la-heterogeneidad-y-la-dinamica-del-agotamiento-de-las-celulas-t-citotoxicas-cd27-en-el-microambiente-tumoral-del-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2390/single-cell-transcriptomic-profiling-reveals-cd27-cytotoxic-t-cell-heterogeneity-and-exhaustion-dynamics-in-colorectal-cancer-tumor-microenvironment 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2389/inmunoterapia-y-toma-de-decisiones-quirurgicas-en-el-cancer-colorrectal-asociado-al-sindrome-de-lynch-implicaciones-para-el-manejo-personalizado-y-la-revision-de-las-guias-clinicas 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2389/immunotherapy-and-surgical-decision-making-in-lynch-syndrome-associated-colorectal-cancer-implications-for-personalized-management-and-guideline-revision 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2385/la-quimioinmunoterapia-permite-implementar-estrategias-adaptativas-en-el-cancer-colorrectal-localmente-avanzado-mss 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2385/chemoimmunotherapy-enables-adaptive-strategies-in-locally-advanced-mss-colorectal-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2384/bloqueo-dual-de-ctla-4-pd-1-frente-a-anti-pd-1-en-cancer-colorrectal-metastasico-msi-h-beneficio-temprano-en-la-supervivencia-y-predictores-clinicos-exploratorios 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2384/dual-ctla-4-pd-1-blockade-versus-anti-pd-1-in-msi-h-metastatic-colorectal-cancer-early-survival-benefit-and-exploratory-clinical-predictors 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2383/mejora-de-la-respuesta-inmunoterapeutica-en-el-cancer-colorrectal-mediante-un-peptido-tumoral-que-penetra-en-el-tumor-y-se-dirige-a-la-neuropilina-1 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2383/enhancing-immunotherapeutic-response-in-colorectal-cancer-with-a-neuropilin-1-targeting-tumor-penetrating-peptide 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2380/terapia-dirigida-a-braf-en-tumores-no-melanoma-con-mutacion-braf-una-revision-sistematica-de-la-eficacia-que-es-amplia-pero-modulada-segun-el-tipo-histologico 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2380/braf-targeted-therapy-in-non-melanomatous-braf-mutant-tumours-a-systematic-review-of-broad-but-histology-modulated-efficacy 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2378/beclin-1-como-biomarcador-de-la-autofagia-en-el-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2378/beclin-1-as-an-autophagy-biomarker-in-colorectal-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2377/biomarcadores-emergentes-para-la-deteccion-precoz-del-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2377/emerging-biomarkers-for-early-detection-of-colorectal-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2372/descubrimiento-de-un-nuevo-y-potente-peptido-dirigido-a-kras-g12v-con-actividad-antiproliferativa-contra-celulas-de-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2372/discovery-of-a-novel-and-potent-kras-g12v-targeting-peptide-with-antiproliferative-activity-against-colorectal-cancer-cells 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2371/los-factores-clinicos-estan-mas-fuertemente-asociados-con-el-pronostico-que-las-alteraciones-geneticas-en-el-cancer-colorrectal-de-inicio-temprano-un-estudio-retrospectivo-de-cohortes 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2371/clinical-factors-are-more-strongly-associated-with-prognosis-than-genetic-alterations-in-early-onset-colorectal-cancer-a-retrospective-cohort-study 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2370/un-mecanismo-dual-de-evasion-inmune-moldea-el-panorama-genetico-e-inmunogenico-de-los-tumores-colorrectales-con-deficiencia-en-la-reparacion-de-errores 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2370/dual-mechanism-of-immune-escape-shapes-the-genetic-and-immunogenic-landscape-of-mismatch-repair-deficient-colorectal-tumours 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2365/la-decoccion-sanwu-huangqin-induce-la-ferroptosis-en-las-celulas-de-cancer-colorrectal-al-activar-la-ferritinafagia-mediada-por-ncoa4-fth1 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2365/sanwu-huangqin-decoction-induces-ferroptosis-in-colorectal-cancer-cells-by-triggering-ncoa4-fth1-mediated-ferritinophagy 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2363/dirigirse-a-la-ferroptosis-para-superar-la-radioresistencia-y-mejorar-la-inmunoterapia-en-el-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2363/targeting-ferroptosis-to-overcome-radioresistance-and-enhance-immunotherapy-in-colorectal-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2362/los-degradadores-moleculares-que-se-unen-a-hur-suprimen-el-cancer-colorrectal-con-mutacion-en-el-gen-braf 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2362/molecular-glue-degraders-of-hur-suppress-braf-mutant-colorectal-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2361/analisis-de-los-factores-de-riesgo-y-las-diferencias-sexuales-en-el-cancer-colorrectal-hallazgos-basados-en-la-evidencia-actual 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2361/exploring-risk-factors-and-sex-differences-in-colorectal-cancer-insights-from-current-evidence 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2357/sonda-fluorescente-de-infrarrojo-cercano-nir-ii-dirigida-a-vegfr2-para-la-obtencion-de-imagenes-precisas-y-la-guia-quirurgica-del-cancer-de-ovario 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2357/vegfr2-targeted-nir-ii-fluorescent-probe-for-precise-imaging-and-surgical-navigation-of-ovarian-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2352/timel-la-integracion-de-aprendizaje-profundo-y-metodos-estadisticos-revela-patrones-espaciales-del-estroma-y-del-sistema-inmunitario-en-el-cancer-colorrectal-agresivo 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2352/timel-deep-learning-statistical-integration-reveals-spatial-stromal-and-immune-signatures-of-aggressive-colon-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2351/la-lidocaina-potencia-los-efectos-antitumorales-del-sorafenib-y-el-gw5074-en-celulas-de-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2351/lidocaine-enhances-antitumor-effects-of-sorafenib-and-gw5074-in-colorectal-cancer-cells 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2349/la-combinacion-del-inhibidor-de-kras-g12c-adagrasib-con-inmunoterapia-anti-pd-1-mejora-la-supervivencia-global-y-previene-la-recurrencia-en-modelos-preclinicos-de-metastasis-cerebrales 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2349/combining-the-kras-g12c-inhibitor-adagrasib-with-anti-pd-1-immunotherapy-improves-overall-survival-and-prevents-recurrence-in-preclinical-models-of-brain-metastasis 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2340/hidrogel-anaerobico-inyectable-que-contiene-clostridium-butyricum-para-la-administracion-local-de-hidrogeno-en-el-tratamiento-del-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2340/injectable-anaerobic-hydrogel-loading-clostridium-butyricum-for-local-hydrogen-therapy-against-colorectal-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2338/ausencia-de-coexistencia-entre-la-amplificacion-de-her2-y-la-inestabilidad-de-microsatelites-deficiencia-de-reparacion-de-errores-dmmr-msi-en-una-amplia-cohorte-multicentrica-de-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2338/absence-of-co-occurrence-between-her2-amplification-and-dmmr-msi-in-a-large-multicentric-colorectal-cancer-cohort 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2337/impacto-de-la-certificacion-del-oncologo-medico-en-los-resultados-de-supervivencia-en-el-cancer-colorrectal-metastasico-evidencia-del-estudio-observacional-scrum-japan-monstar-screen 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2337/impact-of-medical-oncologist-certification-on-survival-outcomes-in-metastatic-colorectal-cancer-evidence-from-the-scrum-japan-monstar-screen-observational-study 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2334/tratamiento-satisfactorio-del-cancer-colorrectal-metastasico-con-mutacion-braf-v600e-y-disfuncion-hepatica-mediante-una-terapia-basada-en-encorafenib 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2334/successful-management-of-braf-v600e-mutated-metastatic-colorectal-cancer-with-liver-dysfunction-using-encorafenib-based-therapy 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2333/farmacoterapia-personalizada-del-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2333/personalized-pharmacotherapy-of-colorectal-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2332/desarrollo-y-evaluacion-in-vivo-de-marcadores-de-pet-marcados-con-18-f-que-se-unen-de-forma-covalente-al-kras-g12c-para-el-diagnostico-no-invasivo-del-cancer-y-el-seguimiento-del-tratamiento 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2332/development-and-in-vivo-evaluation-of-18-f-labeled-pet-tracers-covalently-targeting-kras-g12c-for-noninvasive-cancer-diagnosis-and-therapy-monitoring 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2331/de-la-dosis-a-la-exposicion-una-nueva-perspectiva-sobre-los-fluoropirimidinicos-como-posibles-moduladores-de-los-puntos-de-control-inmunitario-en-los-canceres-gastrointestinales 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2331/from-dose-to-exposure-rethinking-fluoropyrimidines-as-immune-checkpoint-partners-in-gastrointestinal-cancers 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2330/terapia-con-celulas-t-modificadas-con-receptores-quimericos-dirigidos-a-la-guanilato-ciclasa-2c-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2330/guanylyl-cyclase-2c-targeted-chimeric-antigen-receptor-t-cell-therapy-in-patients-with-metastatic-colorectal-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2322/investigacion-de-la-eficacia-del-propranolol-en-el-tratamiento-del-estres-cronico-combinado-con-cancer-colorrectal-en-ratones-y-su-potencial-antitumoral 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2322/investigating-the-efficacy-of-propranolol-in-treating-chronic-stress-combined-with-colorectal-cancer-in-mice-and-its-antitumor-potential 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2318/sorafenib-anclado-sobre-negro-de-carbon-como-un-electrocatalizador-redox-molecular-estable-para-la-oxidacion-de-tioles-y-la-deteccion-en-el-punto-de-atencion-en-celulas-cancerosas 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2318/anchored-sorafenib-on-carbon-black-as-a-stable-molecular-redox-electrocatalyst-for-thiol-oxidation-and-point-of-care-sensing-in-cancer-cells 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2317/alteraciones-especificas-del-subtipo-en-el-transporte-de-cobre-asociadas-con-las-mutaciones-de-kras-en-lineas-celulares-isogenicas-de-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2317/subtype-specific-alterations-in-copper-trafficking-associated-with-kras-mutations-in-isogenic-colorectal-cancer-cell-lines 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2316/la-delecion-de-egfr-en-celulas-mieloides-reprograma-el-paisaje-inmunosupresor-del-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2316/egfr-deletion-in-myeloid-cells-reprograms-the-immunosuppressive-landscape-of-colorectal-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2314/papel-emergente-de-los-conjugados-anticuerpo-farmaco-en-las-neoplasias-gastrointestinales 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2314/emerging-role-of-antibody-drug-conjugates-in-gastrointestinal-malignancies 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2313/la-modulacion-dirigida-del-tnf-potencia-la-actividad-de-los-anticuerpos-bispecificos-que-activan-las-celulas-t-en-tumores-solidos-transformando-tumores-frios-en-tumores-calientes 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2313/targeted-tnf-potentiates-the-activity-of-bispecific-t-cell-engagers-in-solid-tumors-by-turning-cold-tumors-hot 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2311/revision-exhaustiva-de-la-inmunoterapia-en-el-cancer-colorrectal-desde-los-mecanismos-hasta-las-intervenciones-de-enfermeria 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2311/comprehensive-review-of-immunotherapy-in-colorectal-cancer-from-mechanisms-to-nursing-interventions 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2310/kras-g12r-en-el-cancer-de-pancreas-por-que-esta-mutacion-resiste-a-las-estrategias-inhibidoras-actuales 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2310/kras-g12r-in-pancreatic-cancer-why-this-mutation-resists-current-inhibitor-strategies 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2306/discriminacion-precisa-de-polimorfismos-de-un-solo-nucleotido-mediante-el-ensamblaje-de-sondas-de-bloqueo-mediadas-por-pna-y-la-amplificacion-por-circulo-rodante-utilizando-pna-modificado-quimicamente 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2306/precision-discrimination-of-single-nucleotide-polymorphisms-via-chemically-engineered-pna-mediated-padlock-probe-assembly-and-rolling-circle-amplification 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2305/avances-recientes-en-las-plataformas-de-biosensores-que-utilizan-la-caracterizacion-de-biomarcadores-exosomicos-para-el-diagnostico-del-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2305/recent-advances-in-biosensing-platforms-utilizing-exosomal-biomarker-profiling-for-cancer-diagnosis 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2303/sintesis-y-evaluacion-preclinica-de-89-zr-dfo-atezolizumab-para-la-imagen-pet-inmunitaria-en-el-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2303/synthesis-and-preclinical-evaluation-of-89-zr-dfo-atezolizumab-for-immuno-pet-imaging-in-colorectal-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2302/mas-alla-del-5-fluorouracilo-convencional-estrategias-recientes-de-quimica-medicinal-para-mejorar-su-eficacia-antitumoral 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2302/beyond-conventional-5-fluorouracil-recent-medicinal-chemistry-strategies-to-enhance-its-anticancer-efficacy 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2301/un-nuevo-inhibidor-no-competitivo-de-p97-vcp-induce-apoptosis-y-autofagia-para-suprimir-el-crecimiento-del-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2301/a-novel-non-competitive-p97-vcp-inhibitor-induces-apoptosis-and-autophagy-to-suppress-colorectal-cancer-growth 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2300/un-estudio-aleatorizado-que-compara-encorafenib-cetuximab-y-folfiri-frente-a-folfiri-con-o-sin-bevacizumab-en-cancer-colorrectal-con-mutacion-braf-v600e-cohorte-3-del-estudio-breakwater 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2300/a-randomised-study-of-encorafenib-cetuximab-and-folfiri-versus-folfiri-with-or-without-bevacizumab-in-braf-v600e-mutant-colorectal-cancer-breakwater-cohort-3 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2299/la-produccion-a-escala-clinica-de-celulas-tcr-t-durante-10-dias-utilizando-il-2-7-15-y-tgf-promueve-tempranamente-fenotipos-de-memoria-y-similares-a-celulas-residentes-en-los-tejidos-y-una-robusta 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2299/clinical-scale-10-day-tcr-t-cell-manufacturing-using-il-2-7-15-and-tgf-promotes-early-memory-and-tissue-resident-like-phenotypes-and-robust-antitumor-activity-in-vitro 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2287/estudio-computacional-de-los-complejos-supramoleculares-de-actinonina-cucurbiturilo-8-para-la-terapia-del-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2287/computational-study-of-actinonin-cucurbit-8-uril-supramolecular-complexes-for-colorectal-cancer-therapy 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2286/secuenciacion-rapida-de-proxima-generacion-in-situ-an-alternative-to-single-gene-and-send-out-testing-in-non-small-cell-lung-cancer-and-colorectal-cancer-in-a-community-pathology-laboratory-setting 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2286/rapid-on-site-next-generation-sequencing-an-alternative-to-single-gene-and-send-out-testing-in-non-small-cell-lung-cancer-and-colorectal-cancer-in-a-community-pathology-laboratory-setting 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2281/la-senalizacion-de-cxcr3-favorece-el-reclutamiento-de-celulas-t-delta-one-y-la-eficacia-antitumoral-en-el-cancer-colorrectal 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2281/cxcr3-signaling-promotes-delta-one-t-cell-recruitment-and-antitumor-efficacy-in-colorectal-cancer 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2278/analisis-integrativo-de-biomarcadores-circulantes-del-cancer-colorrectal-mediante-la-combinacion-de-espectroscopia-de-infrarrojo-medio-y-metabolomica-dirigida 2026-06-23 monthly 0.5 https://crcwarriors.org/articulo/2278/integrative-analysis-of-circulating-biomarkers-of-colorectal-cancer-combining-mid-infrared-spectroscopy-and-targeted-metabolomics 2026-06-23 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nuevas-funcionalidades-en-el-buscador-de-ensayos-clinicos-mapa-interactivo-filtros-avanzados-y-mas 2026-06-22 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nueva-experiencia-de-noticias-cientificas-ia-personalizada-traduccion-en-tiempo-real-y-mucho-mas 2026-06-22 monthly 0.5 https://crcwarriors.org/news-detail.php?id=lanzamos-la-beta-de-crc-warriors-buscamos-testers 2026-06-20 monthly 0.5 https://crcwarriors.org/news-detail.php?id=glosario-de-farmacos-2-0-mas-inteligente-mas-completo-mas-potente 2026-06-22 monthly 0.5 https://crcwarriors.org/combinaciones/63 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/62 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/33 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/34 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/36 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/52 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/11 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/45 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/42 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/1 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/12 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/48 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/13 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/30 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/53 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/3 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/5 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/50 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/15 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/39 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/59 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/2 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/49 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/56 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/64 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/38 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/4 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/16 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/19 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/54 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/51 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/40 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/55 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/18 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/61 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/41 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/20 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/21 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/22 2025-12-07 monthly 0.5 https://crcwarriors.org/help/getting-started.php 2026-06-01 monthly 0.4 https://crcwarriors.org/help/clinical-trials-guide.php 2026-06-01 monthly 0.4 https://crcwarriors.org/help/understanding-mutations.php 2026-06-01 monthly 0.4 https://crcwarriors.org/help/medication-database.php 2026-06-01 monthly 0.4 https://crcwarriors.org/help/privacy-security.php 2026-06-01 monthly 0.4 https://crcwarriors.org/help/faq.php 2026-06-01 monthly 0.4